Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02716347 2015-08-18
Amino Acid Inhibitors of Cytochrome P450
The technology described herein provides methods of inhibiting cytochrome P450
6 enzymes. The technology also provides methods of enhancing the
therapeutic effect of
drugs that are metabolized by cytochrome P450 enzymes, methods of decreasing
the toxic
effects of drugs that are metabolized to toxic by-products by cytochrome P450
enzymes,
methods of increasing oral bioavailability of drugs that are metabolized by
cytochrome
p450 enzymes, and methods of curing diseases that are caused or exacerbated by
the
activity of cytochrome P450 enzymes.
Background
Cytochrome P450 proteins (CYP(s), or alternatively P450(s)) are a family of
enzymes involved in the oxidative metabolism of both endogenous and exogenous
compounds. P450 enzymes are widely distributed in the liver, intestines and
other tissues
(Krishna et al., Clinical Pharmacokinelics. 26:144-160, 1994). P450 enzymes
catalyze
the phase I reaction of drug metabolism, to generate metabolites for
excretion. The
classification of P450s is based on homology of the amino acid sequence
(Slaughter et al
The Annals of Phartnacotherapy 29:619-624, 1995). In mammals, there is over
55%
homology of the amino acid sequence of CYP subfamilies. The differences in
amino acid
sequence constitute the basis for a classification of the superfamily of
cytochrome P450
enzymes into families, subfamilies and isozymes.
When bound to carbon monoxide (CO), the CYP proteins display a maximum
absorbance (peak) at 450 am in the visible spectra, from which its name,
cytochrome P450
is derived (Omura et al., J. Biol. Chem. 239:2370, 1964). The proteins contain
an iron
cation and are membrane bound enzymes that can carry out electron transfer and
energy
transfer. Over 200 genes encoding cytochrome P450 proteins have been
identified. Those
genes have been divided among more than 30 gene families, which are organized
into
subfamilies that vary in regulation of gene expression and in amino acid
sequence
homology, substrate specificity, catalytic activity, and physiological role of
the encoded
enzymes.
Representative cytochrome P450 (CYP) genes and examples of the known
substrates of CYP proteins encoded by those genes are discussed below. See
also the
1
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
discussion in Klassen, ed., Casarett and Doull's Toxicology: The Basic Science
of Poisons,
McGraw-Hill, 1996, pp. 150 ff. Further information about cytochrome P450
substrates,
can be found in Gonzales and other review articles cited above. Current
information
sources available via the Internet include the "Cytochrome P450 Homepage",
maintained
by David Nelson, the "Cytochrome P450 Database", provided by the Institute of
Biomedical Chemistry & Center for Molecular Design, and the "Directory of P450-
containing Systems", provided by Kirill N. Degtyarenko and Peter Fabian.
CYP1A1: diethylstilbestrol, 2- and 4-hydroxyestradiol
CYP1A2: acetaminophen, phenacetin, acetanilide (analgesics), caffeine,
clozapine
(sedative), cyclobenzaprine (muscle relaxant), estradiol, imipramine
(antidepressant), mexillitene (antiarrhythmic), naproxen (analgesic),
riluzole,
tacrine, theophylline (cardiac stimulant, bronchodilator, smooth muscle
relaxant),
warfarin.
CYP2A6: coumarin, butadiene, nicotine
CYP2A13: nicotine
CYP2B1: phenobarbital, hexobarbital
CYP2C9: NSAIDs such as diclofenac, ibuprofen, and piroxicam; oral hypoglycemic
agents such as tolbutamide and glipizide; angiotensin-2 blockers such as
irbesartan,
losartan, and valsartan; naproxen (analgesic); phenytoin (anticonvulsant,
antiepileptic); sulfamethoxazole, tamoxifen (antineoplastic); torsemide;
warfarin,
flurbiprofen
CYP2C19: hexobarbital, mephobarbital, imipramine, clomipramine, citalopram,
cycloguanil, the anti-epileptics phenytoin and diazepam, S-mephenytoin,
diphenylhydantoin, lansoprazole, pantoprazole, omeprazole, pentamidine,
propranolol, cyclophosphamide, progesterone
CYP2D6: antidepressants (imipramine, clomipramine, desimpramine),
antipsychotics
(haloperidol, perphenazine, risperidone, thioridazine), beta blockers
(carvedilol, S-
metoprolol, propafenone, timolol), amphetamine, codeine, dextromethorphan,
fluoxetine, S-mexiletine, phenacetin, propranolol
CYP2E1: acetaminophen; chlorzoxazone (muscle relaxant), ethanol; caffeine,
theophylline; dapsone, general anesthetics such as enflurane, halothane, and
methoxyflurane; nitrosamines
CYP3A4: HIV Protease Inhibitors such as indinavir, ritonavir, lopinavir,
amprenavir,
tipranavir, darunavir, and saquinavir; HIV integrase inhibitors such as
raltegravir,
2
CA 02716347 2010-08-23
WO 2009/105774
PCT/US2009/034915
Hepatitis C virus (HCV) protease inhibitors, benzodiazepines such as
alprazolam,
diazepam, midazolam, and triazolam; immune modulators such as cyclosporine;
antihistamines such as astemizole and chlorpheniramine; HMG CoA Reductase
inhibitors such as atorvastatin, cerivastatin, lovastatin, and simvastatin;
channel
blockers such as diltiazem, felodipine, nifedipine, nisoldipine, nitrendipine,
and
verapamil; antibiotics such as clarithromycin, erythromycin, and rapamycin;
various steroids including cortisol, testosterone, progesterone, estradiol,
ethinylestradiol, hydrocortisone, prednisone, and prednisolone; acetaminophen,
aldrin, alfentanil, amiodarone, astemizole, benzphetamine, budesonide,
carbarnazepine, cyclophosphamide, ifosfamide, dapsone, digitoxin, quinidine
(anti-
arrhythmic), etoposide, flutamide, imipramine, lansoprazole, lidocaine,
losartan,
omeprazole, retinoic acid, FK506 (tacrolimus), tamoxifen, taxol and taxol
analogs
such as taxotere, teniposide, terfenadine, buspirone, haloperidol
(antipsychotic),
methadone, sildenafil, trazodone, theophylline, toremifene, troleandomycin,
warfarin, zatosetron, zonisamide.
CYP6A1: fatty acids
The efficacy of a drug can be dramatically affected by its metabolism in the
body.
In addition, the failure to maintain therapeutically effective amounts of a
drug may also
impact its long-term efficacy. This situation may arise particularly in
treatment of
infectious diseases, such as viral or bacterial infections, where the
inability to maintain an
effective therapeutic dose can lead to the infectious agent(s) becoming drug
resistant. To
avoid the consequences of metabolism and sustain a therapeutically effective
amount of
drugs that are rapidly metabolized in a subject, or a specific tissue of a
subject, the drugs
often must be administered in a sustained release formulation, given more
frequently
and/or administered in higher dose than more slowly metabolized drugs
administered by
the same routes.
A common pathway of metabolism for drugs containing lipophilic moieties is via
oxidation by one or more CYP enzymes. The CYP enzyme pathway metabolizes many
lipophilic drugs to more polar derivatives that are more readily excreted
through the kidney
or liver (renal or biliary routes). That pathway renders many compounds having
strong
biological efficacy that would otherwise be potentially powerful therapeutics
essentially
useless by virtue of their rapid metabolism, which results in short half-lives
in vivo,
particularly where drugs are administered by the oral route.
3
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
Poor bioavailability, particularly oral bioavailability, due to first pass CYP
metabolism, which leads to elimination of drugs via the liver and/or
intestinal routes, is a
major reason for the failure of many drug candidates in clinical trials. Where
extensive
metabolism by intestinal CYP occurs, first pass metabolism can lead to poor
drug
absorption from the GI tract. Similarly, extensive hepatic CYP metabolism can
result in
low circulating (plasma or blood) levels of a drug.
Alteration in drug metabolism by CYP proteins may have undesired or unexpected
consequences. In some instances, metabolic by-products of CYP enzymes are
highly toxic
and can result in severe side effects, cancer, and even death. In other
instances, alterations
in CYP metabolism due to the interaction of agents may produce undesirable
results.
Some examples of drug metabolism by CYP proteins and the effects of other
agents
on the metabolites produced by CYP proteins include:
Acetaminophen: Ethanol up-regulates CYP2E1, which metabolizes acetaminophen
to a reactive quinone. This reactive quinone intermediate, when produced in
sufficient
amounts, causes liver damage and necrosis.
Sedatives: The sedative phenobarbital (PB) up-regulates several P450 genes,
including those of the CYP2B and CYP3A subfamilies. Upregulation of these
enzymes
increases the metabolism and reduces the sedative effects of PB and the
related sedative
hexobarbital.
Antibiotics: The antibiotics rifampicin, rifampin, rifabutin, erythromycin,
and
related compounds are inducers of the CYP3A4 gene and are substrates of the
enzyme
product.
Anti-cancer agents: Taxol and taxotere are potent anti-cancer agents. Both
drugs
are extensively metabolized by CYP3A4 and have poor oral bioavailability.
These drugs
are only efficacious in parenteral formulations, which, due to their poor
solubility
properties, are highly noxious to patients.
Nicotine: CYP2A6 and 2A13 convert nicotine, a non-toxic component of cigarette
smoke, into NNK, a highly potent carcinogen that contributes to lung cancer
from
smoking.
Oral contraceptive/estrogen replacement therapy: Estrogens and estradiols are
the
active ingredients in oral contraceptives and in hormonal replacement
therapies for post-
menopausal women. Women who are also taking antibiotics such as rifampicin or
erythromycin, or glucocorticoids such as dexamethasone, or who smoke, risk
decreased
4
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
efficacy of the estrogen/estradiol treatments due to increased metabolism of
these
compounds by up-regulated CYP3A4 and/or CYP1A2 enzymes.
Dextromethorphan: CYP2D6 metabolizes dextromethorphan to dextrorphan.
Individuals who express high levels of CYP2D6 (so-called rapid metabolizers)
do not
receive therapeutic benefits from dextromethorphan due to extensive first-pass
metabolism
and rapid systemic clearance.
Protease Inhibitors: Protease inhibitors and non-nucleoside reverse
transcriptase
inhibitors currently indicated for use in treatment of HIV or HCV are
typically good
substrates of cytochrome P450 enzymes; in particular, they are metabolized by
CYP3A4
enzymes (see e.g., Sahai, AIDS 10 Suppl 1:S21-5, 1996) with possible
participation by
CYP2D6 enzymes (Kumar et al., J Pharmacol. Exp. Ther. 277(1):423-31, 1996).
Although protease inhibitors are reported to be inhibitors of CYP3A4, some non-
nucleoside reverse transcriptase inhibitors, such as nevirapine and efavirenz,
are inducers
of CYP3A4 (see e.g., Murphy et al., Expert Opin Invest Drugs 5/9: 1183-99,
1996).
Human CYP isozymes are widely distributed among tissues and organs (Zhang et
al., Drug Metabolism and Disposition. 27:804-809, 1999). With the exception of
CYP1A 1 and CYP2A13, most human CYP isozymes are located in the liver, but are
expressed at different levels (Waziers J. Pharmacol. Exp. Then 253: 387,
1990). A
solution to the problem of drug degradation and first-pass metabolism is to
control the rate
of drug metabolism. When the rates of drug absorption and metabolism reach a
steady
state, a maintenance dose can be delivered to achieve a desired drug
concentration that is
required for drug efficacy. Certain natural products have been shown to
increase
bioavailability of a drug. For example, the effect of grapefruit juice on drug
pharmacokinetics is well known. See Edgar et al., Eur. J. Clin. Pharmacol.
42:313,
(1992); Lee et al., Clin. Pharmacol. Ther. 59:62, (1996); Kane et al., Mayo
Clinic Proc.
75:933, (2000). This effect of grapefruit juice is due to the presence of
natural P450-
inhibiting components. Other compounds also have been used for inhibition of
P450. For
example, the HIV-1 protease inhibitor Ritonavir is now more commonly
prescribed for
use in combination with other, more effective HIV protease inhibitors because
of its ability
to "boost" those other compounds by inhibiting P450-mediated degradation.
Present methods of inhibiting cytochrome P450 enzymes are not wholly
satisfactory because of toxicity issues, high cost, and other factors. For
example, using
ritonavir to inhibit cytochrome P450 is not desirable in disorders other than
HIV infection.
It is apparent, therefore, that new and improved methods of inhibiting
cytochrome P450
5
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
enzymes are greatly to be desired. In particular, methods where an inhibitor
can be co-
administered with another biologically active compound that is metabolized by
cytochrome
P450 enzymes are highly desirable.
Summary
The technology described herein provides, among other things, methods and
compounds for inhibiting cytochrome P450 enzymes. The technology also provides
methods of enhancing the therapeutic effect of drugs that are metabolized by
cytochrome
P450 enzymes, methods of decreasing the toxic effects of drugs that are
metabolized to
toxic by-products by cytochrome P450 enzymes, methods of increasing oral
bioavailability
of drugs that are metabolized by cytochrome P450 enzymes, and methods of
curing
diseases that are caused or exacerbated by the activity of cytochrome P450
enzymes.
An advantage of the technology described herein is that it provides improved
inhibitors of cytochrome P450 enzymes. Another advantage is that it provides a
method of
controlling the pharmacokinetic properties of drugs. Another advantage is that
it helps
control the rate of metabolism of drugs. Another advantage is that it controls
the
degradation of drugs. Another advantage is that it enhances the
bioavailability of drugs.
Another advantage is that it enhances the efficacy of drugs. Another advantage
is that it
boosts the efficacy of certain drugs so that the drugs can be administered at
a lower
concentration or dosage thereby reducing their toxicity. Another advantage is
that these
properties can lower the overall cost associated with the treatment of
disorders.
In one aspect, the technology described herein provides both compounds of
formula
(I), and a method of inhibiting a cytochrome P450 monooxygenase enzyme by
contacting
it with a compound of formula (I) having the structure:
R5
R3 R4
R2
>K.N
R6
R1 0 (I)
where:
each RI, R2, R3, R4, R5, and R6 independently is selected from the group
consisting of
H, optionally substituted CI-Ca alkyl, optionally substituted C3-C8
cycloalkyl,
optionally substituted cycloalkylalkyl, optionally substituted aryl,
optionally
substituted aralkyl, optionally substituted heteroaryl, optionally substituted
6
CA 02716347 2010-08-23
WO 2009/105774
PCT/US2009/034915
heteroaralkyl, optionally substituted heterocyclo,- optionally substituted
heterocycloalkylalkyl, -SOn(R), and -(CH2)0_6C0(CH2)0_3-R ;
wherein at least one of RI, R2, R3, R4, R5, and R6 is -S(0)n-(CH2)o-3-
(benzofuranY1),
-(CH2)1.5-N(R)(-S02-benzofuranyl), -C(0),-(CH2)0_3-(benzofurany1),
-(CH2)1.5-N(R)(C(=0)-(benzofuranyl), or C1-C6 alkylene-(benzofuranyl), wherein
said benzofuranyl substituent may be substituted with an optional substituent,
and
wherein the benzofuranyl group is not fused as part of a tricyclic system;
each optional substituent is selected from the group consisting of halo, -CN, -
NO2,
-COõR, -0C(=0)R, -C(=0)N(R)2, -C(=S)R, -C(=S)N(R)2, -SON(R)2, -SR, -SOAR,
-N(R)2, -N(R)C0nR, -NRS(=0)nR, -NRC[¨N(R)]N(R)2, -N(R)N(R)C0nR,
-NRPOnN(R)2, -NRPOOR, oxo, =N-OR, =N-N(R)2, =NR, =NNRC(0)N(R)2,
=NNRCOõR, =NNRS(0)nN(R)2, =NNRS(0)n(R)C1-C8 alkyl, -OR, C1-C8 alkyl, C2-
C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, heterocyclo,
aryl,
and heteroaryl;
each R is independently selected from the group consisting of: H, C1-C8 alkyl,
aryl,
aralkyl, heteroaryl, and heteroaralkyl, and when R is directly bound to a
nitrogen, R
may additionally be selected from -C(0)alkyl , -S(0)11alkyl, C(0)-aryl,
-S(0)11-aryl, or -S(0)11-heteroaryl, wherein when R is a group selected from
aryl,
aralkyl, heteroaryl, heteroaralkyl, -C(0)n-ary1, -S(=O)-aryl, or -S(=0)-
heteroaryl,
the group may substituted with one or more independently selected C1-C6
alkyls;
each n is independently 1 or 2;
provided that at least two of RI, R2, R3, R4, R5, and R6 are not H;
provided that neither R5 nor R6 forms a ring with RI, R2, R3, or R4; and
provided that the compound is not
(C N
"yo N
I-N
I-N
0 00
0 00
0 0
= = =
7
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
101
r\\,
CCH3
1 1
oL 0 /0L 0
0
101 0 0
= ,or =
In another aspect, the technology provides a pharmaceutical composition
comprising a pharmaceutically acceptable diluent, carrier, or excipient and a
compound of
fonnula (I), or any subgrouping thereof such as the compounds in Table I.
In yet another aspect, the technology provides a method of inhibiting
cytochrome
P450 monooxygenase in a subject, including administering to the subject an
effective
amount of a compound according to formula (I).
In still another aspect, the technology provides a method of reducing toxicity
in a
subject of a compound that is metabolized by cytochrome P450 monooxygenase to
a toxic
metabolite, the method including administering to the subject an effective
amount of a
compound according to formula (I).
In some embodiments, where a compound of formula (I) is administered to a
subject, the subject is a patient is suffering from chronic pain, depression,
epilepsy,
psychosis, inflammation, cancer, cardiovascular disease, diabetes,
neurodegenerative
disease such as Alzheimer's disease, and/or infection. In other embodiments,
the patient is
suffering from HCV or HIV infection.
In some embodiments, where a compound of formula (I) is administered with a
drug whose efficacy is compromised due to degradation by cytochrome P450, the
compound is administered prior to, and/or substantially contemporaneously
with, the drug.
In other embodiments, the compound can be administered at least 30 minutes, at
least 1
hour, at least 2 hours, or at least 12 hours prior to administration of the
drug.
In some embodiments, the pharmaceutical composition comprises a compound of
formula (I) and an effective amount of a drug whose efficacy is compromised
due to
degradation by cytochrome P450 monooxygenase. The drug can be, for example,
Cyclosporine, Tacrolimus (FK506), Sirolimus (rapamycin), Indinavir, Ritonavir,
Saquinavir, Felodipine, Isradipine, Nicardipine, Nisoldipine, Nimodipine,
Nitrendipine,
Nifedipine, Verapamil, Etoposide, Tamoxifen, Vinblastine, Vincristine, Taxol,
8
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
Atorvastatin, Fluvastatin, Lovastatin, Pravastatin, Simvastatin, Terfenadine,
Loratadine,
Astemizole, Alfentanil, Carbamazepine, Azithromycin, Clarithromycin,
Erythromycin,
Itraconazole, Rifabutin, Lidocaine, Cisapride, Sertraline, Pimozide,
Triazolam,
Anastrazole, Busulfan, Corticosteroids (dexamethasone, methylprednisone and
-- prednisone), Cyclophosphamide, Cytarabine, Docetaxel, Doxorubicin,
Erlotinib,
Exemestane, Gefitinib, Idarubicin, Ifosphamide, Imatinib mesylate, Irinotecan,
Ketoconazole, Letrozole, Paclitaxel, Teniposide, Tretinoin, Vinorelbine,
quinidine,
alprazolam, diazepam, midazolam, nelfinavir, chlorpheniramine, amlodipine,
diltiazem,
lercanidipine, cerivastatin, estradiol, hydrocortisone, progesterone,
testosterone, alfentanyl,
-- aripiprazole, cafergot, caffeine, cilostazol, cocaine, codeine, dapsone,
dextromethorphan,
domperidone, eplerenone, fentanyl, finasteride, gleevec, haloperidol,
irinotecan, Levo-
Alpha Acetyl Methadol (LAAM), methadone, nateglinide, odansetron, propranolol,
quinine, salmeterol, sildenafil, trazodone, vincristine, zaleplon, zolpidem.,
ixabepilone,
Agenerase (APV), Aptivus (TPV), Crixivan (IDV), Invirase (SQV), Lexiva (FPV),
-- Prezista (DRV), Reyataz (ATV) Viracept (NFV), Elvitegravir, Selzentry,
Vicriviroc,
Telaprevir, Telithromycin, tandospirone or buspirone.
Each of the aspects and embodiments of the technology discussed above can
include one or more of the following embodiments of a compound of formula (I).
In some embodiments, R5 is an otherwise unsubstituted CI-12-4-benzofuranyl,
CH2-
-- 5-benzofuranyl, CH2-6-benzofuranyl, or CH2-7-benzofuranyl. R3 can be H and
R4 can be
selected from the group consisting of H, optionally substituted C1-C8 alkyl,
optionally
substituted C3-C8cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted
aryl, optionally substituted aralkyl, optionally substituted heteroaryl,
optionally substituted
heteroaralkyl, optionally substituted heterocyclo, and optionally substituted
-- heterocycloalkylalkyl. RI can be optionally substituted C1-C8 alkyl. R2 can
be optionally
substituted C1-C8 alkyl. R4 can be optionally substituted alkyl or optionally
substituted
heteroaralkyl. R6 can be H, optionally substituted C1-C8 alkyl, or optionally
substituted
heteroaralkyl. RI and R2 canbe optionally substituted C1-C8 alkyl. R3 can be
H, R4 can be
H, optionally substituted C1-C8 alkyl or optionally substituted heteroaralkyl,
and R6 can be
-- H, optionally substituted C1-C8 alkyl or optionally substituted
heteroaralkyl.
In some embodiments, R3 is an otherwise unsubstituted CH2-4-benzofuranyl, CH2-
5-benzofuranyl, CH2-6-benzofuranyl, or CH2-7-benzofuranyl.
In some embodiments, R4 can be H. In other embodiments, R4 can be H or C1-C8
alkyl. In still other embodiments, R4 can be H. R4 can be H and R5 can be H.
R6 can be
9
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
selected from the group consisting of optionally substituted C1-C8 alkyl,
optionally
substituted C3-C8 cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted
aryl, optionally substituted aralkyl, optionally substituted heteroaryl,
optionally substituted
heteroaralkyl, optionally substituted heterocyclo, and optionally substituted
heterocycloalkylalkyl.
In some embodiments, RI can be an otherwise unsubstituted -CH2-4-benzofuranyl,
-CH2-5-benzofuranyl, -CH2-6-benzofuranyl, or -CH2-7-benzofuranyl.
In some embodiments, a compound is selected from the compounds listed in Table
1.
In some embodiments, one or both of R3 and R4 is heteroarylalkyl.
In some embodiments, one or both of R3 and R4 is heteroarylmethyl.
In some embodiments, the cytochrome P450 monooxygenase is CYP3A4 or
CYP3A5.
The details of one or more examples are set forth in the accompanying reaction
schemes and description. Further features, aspects, and advantages of the
technology will
become apparent from the description, the schemes, and the claims.
Detailed Description
The technology described herein provides compounds and methods for inhibiting
cytochrome P450 (CYP) enzymes. More particularly, the technology provides
methods for
enhancing the therapeutic effect of drugs in which the drug's efficacy is
compromised due
to degradation mediated by cytochrome P450. The methods include administering
compounds or pharmaceutical compositions containing the compounds in any
therapeutic
regimen where one or more primary drugs is metabolized by a CYP. The compounds
or
pharmaceutical compositions can be administered when the primary drug either
becomes
inactive or is converted to a toxic metabolite due to metabolism by a CYP. The
compounds or compositions can inhibit or reduce the rate of degradation of
drugs that are
effective against a variety of diseases and that are degraded by one or more
cytochrome
P450 enzymes. Upon co-administration, the compounds and compositions can, for
example, maintain intracellular concentrations of the drugs at a therapeutic
level for a
sustained period of time. The methods are useful, for example, in treating a
variety of
disorders such as, cardiac arrhythmia, depression, psychosis, chronic pain,
diabetes,
neurodegenerative disease such as Alzheimer's disease, and infections such as
HIV or
HCV. The compounds or compositions can be administered either alone or in
combination
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
with drugs such as analgesics, anti-depressants, anti-psychotics, antibiotics,
anti-
arrhythmics, steroids, anesthetics, muscle relaxants, cardiac stimulants,
NSAIDs, anti-
epileptics, or protease inhibitors, such as HIV or HCV protease inhibitors.
More particularly, in one aspect, the technology provides a compound, its
stereoisomeric forms, and pharmacologically acceptable salts thereof, having
the formula:
R5
R3 R4 I
N R6
R1 0 (I)
where:
each RI, R2, R3, R4, R5, and R6 independently is selected from the group
consisting of
H, optionally substituted CI-Cs alkyl, optionally substituted C3-C8cycloalkyl,
optionally substituted cycloalkylalkyl, optionally substituted aryl,
optionally
substituted aralkyl, optionally substituted heteroaryl, optionally substituted
heteroaralkyl, optionally substituted heterocyclo,- optionally substituted
heterocycloalkylalkyl, -SOn(R), and -(CH2)0_6C0(CH2)0_3-R ;
wherein at least one of RI, R2, R3, R4, R5, and R6 is -S(0)-(CH2)0_3-
(benzofuranyl),
-(CH2)1_5-N(R)(-S02-benzofuranyl), -C(0)0-(CH2)0_3-(benzofuranyl),
-(CH2)1.5-N(R)(C(=0)-(benzofuranyl), or C1-C6 alkylene-(benzofuranyl), wherein
said benzofuranyl substituent may be substituted with an optional substituent,
and
wherein the benzofuranyl group is not fused as part of a tricyclic system;
each optional substituent is selected from the group consisting of halo, -CN, -
NO2,
-COAR, -0C(=0)R, -C(=0)N(R)2, -C(=S)R, -C(=S)N(R)2, -SON(R)2, -SR, -SOAR,
-N(R)2, -N(R)C0R, -NRS(=0)0R, -NRC[=-N(R)]N(R)2, -N(R)N(R)C0nR,
-NRPOnN(R)2, -NRPOnOR, oxo, =N-OR, =N-N(R)2, =NR, =NNRC(0)N(R)2,
=NNRCOnR, =NNRS(0)N(R)2, =NNRS(0)11(R)C1-C8 alkyl, -OR, CI-Cs alkyl, C2-
C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, heterocyclo,
aryl,
and heteroaryl;
each R is independently selected from the group consisting of: H, C1-C8 alkyl,
aryl,
aralkyl, heteroaryl, and heteroaralkyl, and when R is directly bound to a
nitrogen, R
may additionally be selected from -C(0)alkyl , -S(0)alkyl, -C(0)-aryl,
-S(0)-aryl, or -S(0)-heteroaryl, wherein when R is a group selected from aryl,
11
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
aralkyl, heteroaryl, heteroaralkyl, -C(0)õ-ary1, -S(=0)-aryl, or -S(=O)-
heteroaryl,
the group may substituted with one or more independently selected C1-C6
alkyls;
each n is independently 1 or 2;
provided that at least two of RI, R2, R3, R4, R5, and R6 are not H;
provided that neither R5 nor R6 forms a ring with RI, R2, R3, or R4; and
provided that the compound is not
raN
N
(ON
0 F-1)y N
FIN
0 00 0
0 0 lip 0 0 SI
= /
= =
,
OCH3 Olt
FIN
II
0 00
0 00 Olin
= /
,or =
In one embodiment, subject to the same provisos recited above, the compound is
a
compound where:
each RI, R2, R3, R4, R5, and R6 independently is selected from the group
consisting of
H, optionally substituted C1-C8 alkyl, optionally substituted C3-C8cycloalkyl,
optionally substituted cycloalkylalkyl, optionally substituted aryl,
optionally
substituted aralkyl, optionally substituted heteroaryl, optionally substituted
heteroaralkyl, optionally substituted heterocyclo, optionally substituted
heterocycloalkylalkyl, -S0(R), and -(CH2)0.6COn(CH2)0_3-R;
wherein at least one of RI, R2, R3, -4,
K R5, and R6 is -S0-(benzofuranyl),
-g=0)-(benzofuranyl), -C(=0)0(CH2)1_3-(benzofuranyl), or CI-C6 alkylene-
(benzofuranyl), wherein said benzofuranyl substituent may be substituted with
an
optional substituent and wherein the benzofuranyl group is not fused as part
of a
tricyclic system;
12
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
each optional substituent is selected from the group consisting of halo, -
0C(=0)R,
-C(=0)N(R)2, -C(=S)R, -C(=S)N(R)2, -SON(R)2, -SR, -S0nR, -N(R)2,
-N(R)COõR, -NRS(=0)nR, -NRCH\T(R)]N(R)2, -N(R)N(R)C0nR, -NRPOnN(R)2,
-NRPOnOR, oxo, -OR, C1-C8 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C5-C8
cycloalkenyl, heterocyclo, aryl, and heteroaryl;
each R is independently selected from the group consisting of: H, C1-C8 alkyl,
aryl,
aralkyl, heteroaryl, and heteroaralkyl, and when R is directly bound to a
nitrogen, R
may additionally be selected from -C(0)nalky1 , -S(0)alkyl, -C(0)-aryl,
-S(0)11-aryl, or -S(=O)-heteroaryl, wherein when R is a group selected from
aryl,
aralkyl, heteroaryl, heteroaralkyl, -C(0)-aryl, -S(=O)-aryl, or -S(=0)n-
heteroary1,
the group may substituted with one or more independently selected C1-C6
alkyls;
each n is independently 1 or 2.
In those embodiments where a benzofuranyl substituent group (radical) is
recited,
any benzofuranyl group may be present. Alternatively, where a benzofuranyl
group is
recited the radical may be selected from any one or more of a 4-benzofuranyl,
5-
benzofuranyl, 6-benzofuranyl, or a 7-benzofuranyl radical.
In another aspect, the technology provides a pharmaceutical composition. The
pharmaceutical composition includes a compound according to the technology and
a
pharmaceutically acceptable diluent, carrier, or excipient.
In yet another aspect, the technology provides a method of inhibiting
cytochrome
P450 monooxygenase in a subject. The method includes administering to the
subject an
effective amount of a compound according to the technology.
In yet another aspect, the technology described herein provides a composition
comprising a compound of formula (I) and an effective amount of a drug where
the
efficacy of the drug is compromised due to degradation by cytochrome P450
monooxygenase. In some embodiments, the cytochrome P450 monooxygenase is
CYP3A4 or CYP3A5.
In still another aspect, the technology provides a method of reducing toxicity
in a
subject of a compound that is metabolized by cytochrome P450 monooxygenase to
a toxic
metabolite. The method includes administering to the subject an effective
amount of a
compound according to the technology.
Each of the aspects and embodiments of the technology discussed above can
include one or more of the following embodiments, including the following
embodiments
of a compound of formula (I).
13
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
In some embodiments, R is independently selected from the group consisting of:
C1-C8 alkyl, aryl, aralkyl, heteroaryl, and heteroaralkyl, and when R is
directly bound to
a nitrogen, R may additionally be selected from -C(0)alkyl , -S(0)alkyl, -C(0)-
aryl,
-S(=0)-ary1, or -S(=0)-heteroary1, wherein when R is a group selected from
aryl,
aralkyl, heteroaryl, heteroaralkyl, -C(0)caryl, -S(=0)õ-ary1, or -S(=0)-
heteroary1, the
group may substituted with one or more independently selected C1-C6 alkyls. In
other
embodiments, each R is independently selected from the group consisting of: H,
C1-C8
alkyl, aryl, aralkyl, heteroaryl, and heteroaralky, and when R is directly
bound to a
nitrogen, R may additionally be selected from -S(0)-aryl, or -S(=0)-
heteroaryl,
wherein when R is a group selected from aryl, aralkyl, heteroaryl,
heteroaralkyl,
-S(=0)õ-ary1, or -S(=0)-heteroary1, the group may substituted with one or more
independently selected C1-C6 alkyls. In other embodiments, each R is
independently
selected from the group consisting of: H, C1-C8 alkyl, aryl, aralkyl,
heteroaryl, and
heteroaralky, wherein when R is a group selected from aryl, aralkyl,
heteroaryl,
heteroaralkyl, the group may substituted with one or more independently
selected C1-C6
alkyls. In another embodiment, R is selected from the group consisting of C1-
C8 alkyl,
aryl, aralkyl, heteroaryl, and heteroaralky, each of which may be substituted
with one or
more independently selected CI-C6 alkyls.
In various embodiments, R5 is an otherwise unsubstituted CH2-4-benzofurany1,
CH2-5-benzofuranyl, CH2-6-benzofuranyl, or CH2-7-benzofuranyl. R3 can be H and
R4
can be selected from the group consisting of H, optionally substituted C1-C8
alkyl,
optionally substituted C3-C8cycloalkyl, optionally substituted
cycloalkylalkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally substituted
heteroaryl, optionally
substituted heteroaralkyl, optionally substituted heterocyclo, and optionally
substituted
heterocycloalkylalkyl. RI can be optionally substituted C1-C8 alkyl. R2 can be
optionally
substituted C1-C8 alkyl. R4 can be optionally substituted alkyl or optionally
substituted
heteroaralkyl. R6 can be H, optionally substituted C1-C8 alkyl, or optionally
substituted
heteroaralkyl. RI and R2 canbe optionally substituted C1-C8 alkyl. R3 can be
H, R4 can be
H, optionally substituted C1-C8 alkyl or optionally substituted heteroaralkyl,
and R6 can be
H, optionally substituted C1-C8 alkyl or optionally substituted heteroaralkyl.
In some embodiments, R3 is an otherwise unsubstituted -CH2-4-benzofuranyl,
-CH2-5-benzofuranyl, -CH2-6-benzofuranyl, or -CH2-7-benzofuranyl.
In some embodiments, R4 can be H or C1-C8 alkyl. In other embodiments, R4 can
be H. In another embodiment, R4 can be H and R5 can be H.
14
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
In some embodiments, R6 can be selected from the group consisting of
optionally
substituted C1-C8 alkyl, optionally substituted C3-C8cycloalkyl, optionally
substituted
cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl,
optionally
substituted heteroaryl, optionally substituted heteroaralkyl, optionally
substituted
heterocyclo, and optionally substituted heterocycloalkylalkyl.
In some embodiments, RI can be an otherwise unsubstituted -C1-12-4-
benzofuranyl,
-CH2-5-benzofuranyl, -CH2-6-benzofuranyl, or -CH2-7-benzofuranyl. In another
embodiment, only one of R1 and R3 is -CH2-4-benzofuranyl, -CH2-5-benzofuranyl,
-CH2-
6-benzofuranyl, or -CH2-7-benzofuranyl.
In certain embodiments, a compound is selected from the compounds listed in
Table 1.
In various embodiments, one or both of R3 and R4 is heteroarylalkyl.
In some embodiments, one or both of R3 and R4 is heteroarylmethyl.
In certain embodiments, the cytochrome P450 monooxygenase is CYP3A4 or
CYP3A5.
In various embodiments, the subject is a patient that is suffering from
chronic pain,
depression, epilepsy, psychosis, inflammation, cancer, cardiovascular disease,
diabetes,
and/or infection. The patient can be suffering from HCV or HIV infection.
In some embodiments, the compound is administered prior to, and/or
substantially
contemporaneously with, a drug wherein efficacy of said drug is compromised
due to
degradation by cytochrome P450 monooxygenase. The compound can be administered
at
least 30 minutes, at least 1 hour, at least 2 hours, or at least 12 hours
prior to administration
of the drug.
In certain embodiments, the composition includes an effective amount of a drug
wherein efficacy of said drug is compromised due to degradation by cytochrome
P450
monooxygenase.
This technology described herein also envisions the quaternization of any
basic
nitrogen-containing groups of the compounds disclosed herein. The basic
nitrogen can be
quatemized with any agents known to those of ordinary skill in the art
including, for
example, lower alkyl halides, such as methyl, ethyl, propyl and butyl
chloride, bromides
and iodides; dialkyl sulfates including dimethyl, diethyl, dibutyl and diamyl
sulfates; long
chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides
and iodides;
and aralkyl halides including benzyl and phenethyl bromides. Water or oil-
soluble or
dispersible products can be obtained by such quatemization.
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
By way of illustration, exemplary compounds of formula (I) are shown in the
Table
1 below, although it will be recognized that these examples are merely
illustrative and not
limiting. All shown compounds have an IC50 less than 100 nM for the metabolism
of
dibenzylfluorescein (DFB) by human liver microsomes (Xeno Tech, LLC, Lenexa,
KS).
Where tested, the compound also have an IC50 less than 100 nM for the
inhibition of DFB
utilization by CYP 3A4.
Table 1
,--------
0
Cni i
). II
I
- --c-...
Hrkr 34 ,N
õ HN-
o - o
9 -
0-
Cmpd. 1 Cmpd. 2
-
'14- .w1 N '
N,' N
H N '
0
A
-
0
-.--
Compound 3 Compound 4
rcN,
1
\ \
1 isr1 '0 CH3
H
...-k-,..
0 0 0 ,....i. 0
I--- 0
-H-- Jc 40 40
0 OCH3
0-
Compoundõ.....y,0 5 Cmpd. 6
-s
i. ¨ ----.
. N ,
1 i
0
0 --L=
9- -0 .--,--- ,
L _ H., N , - 0 ,-, k, I
1
'N
¨1.--
-P
i
0¨
Cmpd. 7 Cmpd. 8
16
CA 02716347 2010-08-23
WO 2009/105774
PCT/US2009/034915
-,--
,
'N- ''''' = ---1,,1 ),-, ,, I
H N.' If ,
..,..3c. 0 -I. H N ,,,
1,1
0 0
0---C-0 r":;---------1
I j
--/
Cmpd. 10
Cmpd. 9
hi; N , 0
NI' "NI,
3, I.,
,
t ,N, 1 ,N
.
HN--
õL 00----k''-0 ,------1- ,
1
I ,
\ 7
o-
Cmpd. 11 Cmpd. 12
1
--1
I
'0
H N'
oc
6
,'
,t ,---,
0- 0
N 11
HN--....
0
0' 0 --- 0 -
1
Y
a¨]
Cmpd. 13 Cmpd. 14
,N. H
P
1 . .
N
H N
S. 0 0
.--
..
js,
i
0 q
Cmpd. 15 Cmpd. 16
---,--- N
-----N- ' .
N
J. s
HN' .---- ---
1,
¨ ¨
o,
Cmpd. 17 Cmpd. 18
17
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
\
---<:-1 ,)-- - HN-
,
0, .... --= >_
I N HC N 0 )- _
"
...i.-- oN- ¨
, -0 ,
o- ,o 0"
+ N
o
Cmpd. 19 Cmpd. 20
1 1
) ,N,
HN
I J.
FN 'rl'
- = b - -l-
o o j- , 8 1
-_c --
6-- 'r". o
J!
s-r- 0 Y
b- -
Cmpd. 21 Cmpd. 22
.-L
1 ,N.
--r-
h
1 a ,
oc",s-so - ....,,,, )
0--r-'10 N-- 0
1 I r ..i. L....,...
-i-....
y ,
6---Y
Cmpd. 23 Cmpd. 24
- N --"---- -1,
)
,
1 1 .
I-14 s _ 0
:I
'
----
, b 0-- --.:, N ---
'
-0 Lõ
L II L.- la
. .-).-
cy T i
o
Cmpd. 25 Cmpd. 26
1
j''' ir"----
,t.
11 1,1-11-"C"
- -14
, S 0
0 0 N
oo o --
,---
`OCH3
0_ _ 0¨I
Cmpd. 27 Cmpd. 28
1
õõ---L-L1
,
r
)......õ 14
6- '0 N 01'0 0
-77-' i -
-N,
0- 0--
Cmpd. 29 Cmpd. 30
18
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
o
HN,
0
S- ¨
0 'o
Cmpd. 31 Cmpd. 32
N
N 0
,t d
0 0
o
0
Cmpd. 34
Cmpd. 33
1
0 NH 1
S' '
h b
-0
N
HN
11'1
i
0 S 0 2.
0 Cf -0
0¨
Cmpd. 35 Cmpd. 36
N
9 HNN
N 0
HN HN
,S 0 0 ,S
0 '0 0 -
Cmpd. 37 Cmpd. 38
19
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
. ,
r
,
'1- '1,1-
Etri,....r... _...N
itr1--Tr i- - -......,õ
ti t _ 6 .-C,
I 1
.',..r, i ...,..,,...... \.... ,.......), ,.,
Cmpd. 39 Cmpd. 40
-----.
- :
N
.- ' '.--
,
0--_ .--, ' ,_ . N cy....,.-,k
_-
1 .,
c) ,
H.
- ), s_
o --1,---0 . .
,.... ,., 0-,---o 0
,
...L.P L 11
0 ¨.!
Cmpd. 41 Cmpd. 42
1-
I-N - - ' .
i....A......... ....-4,
0
N
o>_0 .-z.. 0 .-i= _S 0
- t0 ' ' -s"-
r Th
i'f,
0 - ----9
Cmpd. 43 Cmpd. 44
- - - N ----S
N
. ..
`r- -,-
' !
-J
---- NI
----A.-----
0 I , 0
HN- ' IT-- - 1-IN-
0 0,
: 51
,S 0 " ,S '6
0 ,----- ,--0
li
'<\--
Cmpd. 45 Cmpd. 46
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
Nn
N...õ<õ,......--,,,
---,N__---
HN"1"1-(3:4=Th
,---------.. ,
.A.,
, ,-
o
HN" ,---- 14-Th
P
..*., a _ .-1,..
-Y.
0 ,o
b.-----
Cmpd. 48
Cmpd. 47
o
<= 11 1
L__---,-2
00 0 "-- ',S....õ 0
0'1 0
4,-
-
,
6-
Cmpd. 49 _ _ . < , Cmpd..--'i ' 50
,
; i ,
cr-=7c-o -' 0 ,...
()yip -
r---.
Cmpd. 51 Cmpd. 52
s---7 s---,1
11
...11..,
,
. .,
,
I . .,
,s 6 ' ,s, o
,0-; o 0-. : =o -
..,õ
:k. .--,- .1,.
----,-
Cmpd. 53 Cmpd. 54
/ r-------N N --"N
S ' /1 \)---
*r ------"-- , - õ ' .,-,.._,----L....
I ,11. r-
.1 )4,
FIN' ¨Tr- -.
aL 6 1
0,---,.--0 - --
,
o
Cmpd. 55 Cmpd. 56
21
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
)1,, s
4TI,
1-1 NIN
-
, 6- 0 ,.S , , 0
o o_=-0
11
Y Y
o--/ ,
(:)----i
Cmpd. 57 Cmpd. 58
---k-, A '- - -
I -11
0- = ----0 0- = -0 - -
,L
II
0 0-
Cmpd. 59 Cmpd. 60
s- s-
11
1 i
- --1--,
,
- -- _IT '11- ; 1 FN I 1
's_ õ......s ., 0 .,8 , 0
....-"A"-
0-- = '0 0" .1.:"0
1; I
O- o- -
Cmpd. 61 Cmpd. 62
..b
.,
s- ,
õ
-C. N---
! '1
.----=" -..
UN I
=
'-.,
il
0 - ----- 0 '
...1....
0--
Cmpd. 63 Cmpd. 64
N=
1 I
HN' HN
0 ;1 ,
, S, 0 , , ...,,,, 0
1 -- I '.0
1
, ..>õ.,..--, ..ii
...,
-:::-
LY 6-----/
0-
Cmpd. 65 Cmpd. 66
22
CA 02716347 2010-08-23
WO 2009/105774
PCT/US2009/034915
=N
i
r
-0 -0
.....,
;------
1.11' (14-
,.. 0
"0
'1'
Cmpd. 67 Cmpd. 68
i
\---- -,. _.--------...,
N
N,
1 1.11'r 1
0
H4 --.._ =--
, 1
0
1 i
, 03 i
1- =,,, :I..
r b
,
-i o -
0-
Cmpd. 69 Cmpd. 70
----\
S ¨_,
N S'
1 N ,
I
HW
1 1 I
S. 0
.--6 ID ..`
.,,
-,...
'Y'=
0- _J
ô---/
Cmpd. 71 Cmpd. 72
,
,
"S' A
-,1- --N- 1 '
,
N-- " I" ... HN' 1 -14'''
1. ' õS., 0 ).
0-'1.'0 '
...., N
)
S, 0 -1-..
0,
' ' "0
0----i
1
1
0 -/
Cmpd. 73 Cmpd. 74
_
23
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
/
'---,¨.-N N¨N
A \___
' ¨
-
N` 1
NH 1
N
HN '
1 0 A
1+1
i .1 li
,.s., 0 -,. --f-
o= '0 '
2,
6-1 Cmpd. 76
Cmpd. 75
¨..
---. ....e....
Isi =
S -s-1.
,----
N 1 , 'N
MN - it
HN )( 6
.---. o .r.-------
1
#
Cmpd. 77 Cmpd. 78
,
s_ ,s
r,- ,
,
õi! -I¨
N' ,.. 1 ,:,
, ,
, -
!..4 0
0'.= -ID
N
0
0
. 6-1¨
Cmpd. 79 Cmpd. 80
H N-
I
,
( ..
1
1 NI c A
,
FN
CI
0- 'to ,j,, 0 A.
0 j:0 '
L 1
o--
Cmpd. 81 Cmpd. 82
24
CA 02716347 2010-08-23
WO 2009/105774
PCT/US2009/034915
-41
Y" 0
'
)4II
H S. 0
07r'0
0 40 e--
0-j 6.---
Cmpd. 83 Cmpd. 84
,N,)
CtiO AL.
0 -
Cmpd. 85
Cmpd. 86
- .-z=N
' 'N' ,
I.
0-; 0 N-
N -
-L.o
j,
Cmpd. o--
87
Cmpd. 88
õ
" lc -
I II
=- o I 0 A.
0"1 '
0 f
Cmpd. 89 0
Cmpd. 90
S, N
0
k 0 S 00
0
'Yr
Cmpd. 91 Cmpd. 92
CA 02716347 2010-08-23
WO 2009/105774
PCT/US2009/034915
-14- )4-
,
-..,
I I
RC '-'(HN
-4, 6
o 1 -o o_--, -'6
-i
Y ,
6--//
Cmpd. 93 Cmpd. 94
/---,
o, o: 1
' / 1
'
NH
--, H N- ---if-
,k2 0
I
, ...)---
"--0'
Cmpd. 95 Cmpd. 96
,
µ,J ,
i 1 i
--L.,
i
FN 11 1 N.
HN'' ----"--
0--:-'' 0
eL -4
I
Cmpd. 97 Cmpd. 98
,
1 0
L.
1 I N
.1 r
--o
i6 . H N.
N- y: -1
o = . ' -
o'; -o 6
II
,
V : 6- -
Cmpd. 99 Cmpd. 100
,
,-N I
___,!--1 ,S, 0 0
0----'''
, '
r...,_ .
,
6- _ 0---
Cmpd. 101 Cmpd. 102
26
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
,
riN
o '
L.....n.
7.
.... ''''
'N = Tr- S 0 -,-
,a b
o -o
o-j 0---'
Cmpd. 103 Cmpd. 104
,
,A.
,--"C
, \
õi= -"'sy 'N- ;-; Nc Iii I I -1
* \ - S
L'
o o-
Cmpd. 105 Cmpd. 106
z
A
// -' st
14 i\......3LyN
--
(----.
.....S., 0 1 I I
0 6
le = / N" tY
= / 0_, //
Cmpd. 107 Cmpd. 108
i,
.1. ,---
;:rw,,,,(N
) ,N
HN' ' ,
NI\ I 1 o 40
----o --C-3
1
1
,..,
0/ ---.1'
,
. /
Cmpd. 109 Cmpd. 110
),.
,
N
õ ,,N. N. ,. N.
, ..
N- -2- cy, .'":-to 0 ,...õ-, '-
'''
,,.
,
0
0____/
--, --= ;.õ1,
Cmpd. 111 Cmpd. 112
27
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
If N
--:- . ..,,,
1 A 1 r:'I
,
6-
0%-0
0
-:--
-.--
1 !
)
0-1/ 46_1
Cmpd. 113 Cmpd. 114
-I,
r
N. )1
N
S- 0 s' 0 o
, S. 0 )-
0 0
'A.
0, (/----=
Cmpd. 115
. Cmpd. 116
,...
,
---,..
eso 0.,... 0 .1..
5-- 0/ 0
--i-
/
= 0
Cmpd. 117 Cmpd. 118
..,
I )\
'=
zit. L ,N, I
NI, li ,
y_ .2., 0
0 1 0 ,S -0 0 .,,,. ,---"
,.-.
T i
Cmpd. 119 Cmpd. 120
I 1------- ._ ,
-L
v;)õ...õ,9,
I
\ I 0 _-_,S.;..
..õ...õ--..õ 0 , 0
,,,,,,.,
40, 0 r 1
0 \
0___ll õ
Cmpd. 121 Cmpd. 122
28
CA 02716347 2010-08-23
WO 2009/105774
PCT/US2009/034915
u , --;--- ...)
1
tt
N-
Htsr .
0-..0 ..
1
A
0- 6- _.y
Cmpd. 123 Cmpd. 124
s,
s il --
.,
opd:'crj
t, ,N:1
HN N"-s,.. Htsr -11
I .-- 0 --.1-=
,S, 0
0--. ".-0 I
0 -S 1
,( -
,
,
----N' 0¨
= /
Cmpd. 125
Cmpd.
S
1 -N I
--L,
0----. , -
I
X HN ' N'
I
I II
0 -' $ ,..
01:0 C:I' ' \ 0 '
,
b-.
Cmpd.
Cmpd. 127 Cmpd. 128
S
N,
,
i
' C)= r--)--
)
1
HN
l4,..
/N-----r--'-'14-1-r ---1,
1 ---1 , I
\ i j
0 ..---s N¨
0 ...0
--;-..
y., )
0
0-
Cmpd. 129 Cmpd. 130
29
CA 02716347 2010-08-23
WO 2009/105774 PCT/US:0091/034915
,
11
1 11
-
,
-1 "s--- o
HN-- 'N'
,0 1 Y
0_ ---- II
isr¨'
\,.==..._=1
0-- -
Cmpd. 131 Cmpd. 132
el S
S'
,..y...;;
N tst'
H
0- )
H N '
S\ 1
----- /
= .4. ,..,
11
Cmpd. 133 a]
Cmpd. 134
, 44 o
i,
õ _
S' ,..
s' 14 s'so
N
0' I
1 )4_
H N-
I! !
õ6, o -1,-. k 6
o ' :zo o ' o
r-
1 1 ( 1
6--1
Cmpd. 135 Cmpd. 136
0
11,-,
.'S..===
L'Ill
HN µ.".
I
.
S,... ,..õ---, 2S. 01' 'K
0 '0 ,---
0r 1
./
0----,
Cmpd. 137 Cmpd. 138
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
....N
, \ "
N' N-----9 L.
i
HN-
-N,
H NyõN,
I,
o
So 0
o= o
Y
Cmpd. 139 Cmpd. 140
i
-I. 1
N.,õ.:=-,,N.'),,,,,,A1-õ. 1 i
iI
Nõ,-S-, 0 ......õ---..,,õ A , ,=
0 .0
S 0
,
40 IV' 0,-,,,,,o
/ Y
=
0------'
Cmpd. 141
Cmpd. 142
-8,
N
Y N-.
N- X ,N,
. ;..r 11' -11.-
- .
o 1 I
- 6
H N" - 0- 0
).
- S d
0- 0
11
. .1
0- --,
0 ¨
Cmpd. 143 Cmpd. 144
1
(.,
I I ,
0,...s0 N- .., 0 ....õ...¨....õ
- =S' 0
" 15' 0
40 ,..., ..k.
= 0_ ..,,
Cmpd. 145 Cmpd. 146
31
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
¨
v N
,, . A : ,- - õ.= - 7.
HN"'
-'- - 0 'µND A 0 ?.
çII
i 1
,
1- ---
... õ%,
'y
0---// 0 ---1/
Cmpd. 147 Cmpd. 148
,N
..i,.. , .
...
1 : N.
-N...
HN" ¨
= ,
-e, 6 )- , s 0 ).
N-- - - = ==
0' i '-'0
,..
sz.-- ,--'=
-I-
a¨
Cmpd. 149
Cmpd. 150
I
S. i ,11- N ,-------s
'
µIsl- - -P= 0" 0 ,
ON
,N,
11-
,
0 6 A.
,=.1 ,,,' )
' r 9
0--
Cmpd. 151
Cmpd. 152
P - 1 0
N' ,...,-------' = ,
a. ,- a I I
--- , ,- -y,
isl
1
HNX -1'4'' ,J, r,--'''
Q 'I
6-0 0
' 0 .}.
, -- , ---0
,
11
6- - ,
. i
Cmpd. 153
Cmpd. 154
---.
8
r,t4 ...---k-----..
=-1--
2--1
....), r4. '--N- -N-
1
-
11 , 6.õ 000
1
0_i
Cmpd. 155 Cmpd. 156
32
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
--s
--i, = -,
_I
N
H N -ir ''.1 1 1--- N
_ k, . 0
0 0 ,,,
'
3.. ' T
s , _ . 0
Cmpd. 154
Cmpd. 158
)7-14
_ ..,
l, k
I
S
n
1 isi, , r- r
õ1., N,
S, 0 N:, I ir 1
=-i- ,..._ c,_o o ,
1,
.1
-,'
'0
0
Cmpd. 159 Cmpd. 160
.."----,1
----,-- o
-1--
'--- ' )
,N-,,,,,
S
4-
Cmpd. 161 Cmpd. 162
o
o'
)-.,---'-:
.1--
r
H N
NN- 1
`i---
i I - Htsr---4--- ----T -
); 0 SO2 0
--c- ''.0
r----C r---(\
--0,
Cmpd. 163 Cmpd. 164
-s S
.J:.
1 N N 4 's
N., ¨ -1-. .N. 1
I ll ,N. '- ir ,
_, 0 )... HN'
N - , ,
0%10
,S, 0 L.õ -.
..--õ.."
.1
0--/
Cmpd. 165
Cmpd. 166
33
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
I
L L
r 0 0 ---
Cmpd. 167 Cmpd. 168
0
HN"
HN- NN-
0- -0 S
0
Cmpd. 169 Cmpd. 170
o'
N N
H N
0
HN" irN
.6o2 L_ s
-o
-o
Cmpd. 171 Cmpd. 172
s-
-11
-s
0N1
0
a
Cmpd. 173 Cmpd. 174
s-
1
JN.
= ,
HN-
0
0 0 ,S, 0
0_=0'
0
Cmpd. 175
Cmpd. 176
34
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
/ 0
r s
,N z
H N
!I
0
0 o'N
OC H3
0
9-
Cmpd. 177
Cmpd. 178
The term "pharmaceutically effective amount" or "therapeutically effective
amount" or "therapeutic dose" or "efficacious dose" refers to an amount that,
when
administered to a subject, is effective in inhibiting cytochrome P450 enough
to reduce or
prevent the in vivo degradation of a co-administered drug and thereby improve
the
pharmacokinetics of the drug ancUor boost its efficacy. The term "treating" as
used herein
refers to the alleviation of symptoms of a particular disorder in a subject,
such as a human
patient, or the improvement of an ascertainable measurement associated with a
particular
disorder. The term "prophylactically effective amount" refers to an amount
effective in
preventing an infection, for example an HIV infection, in a subject, such as a
human
patient. As used herein, a "subject" refers to a mammal, including a human.
The term "co-administered drug" or "drug" refers to a compound given to a
patient
or subject, which may be a human, for prophylactic or therapeutic treatment.
For example,
a drug or a co-administered drug may be a compound or composition listed in
the U.S.
Pharmacopeia, or the Physician's Desk Reference. In specific embodiments a
drug or co-
administered drug is selected from Cyclosporine, Tacrolimus (FK506), Sirolimus
(rapamycin), Indinavir, Ritonavir, Saquinavir, Felodipine, Isradipine,
Nicardipine,
Nisoldipine, Nimodipine, Nitrendipine, Nifedipine, Verapamil, Etoposide,
Tamoxifen,
Vinblastine, Vincristine, Taxol, Atorvastatin, Fluvastatin, Lovastatin,
Pravastatin,
Simvastatin, Terfenadine, Loratadine, Astemizole, Alfentanil, Carbamazepine,
Azithromycin, Clarithromycin, Erythromycin, Itraconazole, Rifabutin,
Lidocaine,
Cisapride, Sertraline, Pimozide, Triazolam, Anastrazole, Busulfan,
Corticosteroids
(dexamethasone, methylprednisone and prednisone), Cyclophosphamide,
Cytarabine,
Docetaxel, Doxorubicin, Erlotinib, Exemestane, Gefitinib, Idarubicin,
Ifosphamide,
Imatinib mesylate, Irinotecan, Ketoconazole, Letrozole, Paclitaxel,
Teniposide, Tretinoin,
Vinorelbine, telithromycin, quinidine, alprazolam, diazepam, midazolarn,
nelfinavir,
chlorpheniramine, amlodipine, diltiazem, lercanidipine, cerivastatin,
estradiol,
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
hydrocortisone, progesterone, testosterone, alfentanyl, aripiprazole,
buspirone, cafergot,
caffeine, cilostazol, cocaine, codeine, dapsone, dextromethorphan, docetaxel,
domperidone, eplerenone, fentanyl, finasteride, gleevec, haloperidol,
irinotecan, Levo-
Alpha Acetyl Methadol (LAAM), methadone, nateglinide, odansetron, propranolol,
quinine, salmeterol, sildenafil, terfenadine, trazodone, vincristine,
zaleplon, zolpidem.,
ixabepilone, Agenerase (APV), Aptivus (TPV), Crixivan (IDV), Invirase (SQV),
Lexiva
(FPV), Prezista (DRV), Reyataz (ATV) Viracept (NFV), Elvitegravir, Selzentry,
Vicriviroc, Telaprevir, Telithromycin, tandospirone or buspirone. A drug may
also be a
compound that, because of its metabolism in a subject, may not otherwise be
effective for
treating a condition in the subject unless administered with a compound that
inhibits CYP
activity.
The term "antiretroviral agent" as used herein refers to a compound that
inhibits the
ability of a retrovirus to effectively infect a host. Antiretroviral agents
can inhibit a variety
of process including the replication of viral genetic materials, or entry of
retroviruses into
cells. In some embodiments, antiretroviral agents are selected from the group
consisting
of: protease inhibitor, a reverse transcriptase inhibitor, and a viral fusion
inhibitor. In other
embodiments the antiretroviral agents are selected from the group consisting
of: abacavir,
didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zidovudine,
elvucitabine,
apricitabine, zalcitabine, delavirdine, efavirenz, nevirapine, rilpivirine,
etravirine,
atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, Kaletra,
nelfinavir, ritonavir,
saquinavir, tipranavir, enfuvirtide, maraviroc, vicriviroc, raltegravir,
elvitegravir,
interferon, albuferon, telaprevir, boceprevir, and viramidine.
The term "lipophilic group" as used herein refers to a group that, when a part
of a
compound, increases the affinity or propensity of the compound to bind, attach
or dissolve
in fat, lipid or oil rather than water. A measure of the lipophilicity or
hydrophobicity of
compounds of the technology can be calculated using the Hansch equation:
Log 1/C = kP
where C is the concentration of a compound in a given solvent and P is the
hydrophobicity. Details of this method can be obtained from J. Amer. Chem.
Soc,
86:5175 (1964) and Drug Design I, edited by E. J. Ariens, Academic Press
(1971), both of
which are hereby incorporated by reference in their entireties.
Examples of a typical lipophilic group include, but are not limited to, alkyl
groups
such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-
pentyl, isopentyl,
neopentyl, amyl, n-hexyl, n-heptyl, cyclohexyl, cycloheptyl, octyl, nonyl,
decyl, undecyl,
36
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
and dodecyl, alkenes such as ethylene, propylene, butene, pentene, hexene,
cyclohexene,
heptene, cycloheptene, octene, cyclooctene, nonene, decene, undecene,
dodecene, 1,3-
butadiene, alkynes such as propyne and butyne, aryls such as phenyl, naphthyl,
anthracenyl, phenanthrenyl, fluorenyl, aralkyls such as benzyl, heterocyclyls
such as
tetrahydrothiophene, dihydrobenzofuran, heteroaryls such as pyrrole, furan,
thiophene,
pyrazole, thiazole, indole, carbazole, benzofuran, benzothiophene, indazole,
benzothiazole,
purine, pyridine, pyridazine, pyrazine, triazine, quinoline, acridine,
isoquinoline, and
phenanthroline.
For small groups containing heteroatom substituents, such as small
heterocycles
with a high ratio of heteroatoms to carbon atoms, the introduction of
substituents that
reduce the heteroatom to carbon atom ratio renders the group lipophilic. For
example, a
triazole ring can be rendered more lipophilic by the introduction of alkyl
substituents.
Similarly, non-lipophilic substituents such as hydroxy or amido can be
rendered lipophilic
by introducing additional carbon atoms, for example by exchanging a
hydroxymethyl
group to a hydroxybenzyl group, or by exchanging a carboxamido group to a
dialkyl
carboxamido group.
The term "substituted", whether preceded by the term "optionally" or not, and
substitutions contained in formulas of this technology, include the
replacement of one or
more hydrogen radicals in a given structure with the radical of a specified
substituent.
When more than one position in a given structure can be substituted with more
than one
substituent selected from a specified group, the substituents can be either
the same or
different at every position (for example, in the moiety -N(R)2, the two R
substituents can
be the same or different). In those embodiments where a structure can be
optionally
substituted, any or all of the hydrogens present may be replaced by
substituents. In some
embodiments, 0-3 hydrogen atoms may be replaced. In other embodiments, 0 or 1
hydrogen atoms may be replaced. Substituents advantageously enhance cytochrome
P450
inhibitory activity in permissive mammalian cells, or enhance deliverability
by improving
solubility characteristics or pharmacokinetic or pharmacodynamic profiles as
compared to
the unsubstituted compound. Enhancements to cytochrome P450 inhibitory
activity,
deliverability and pharmacokinetic parameters achieved by the addition of
substituents
may result in synergistic enhancement of a compound's action and suitability
for use in
one or more applications.
Combinations of substituents and variables envisioned by this technology are
limited to those that result in the formation of stable compounds. The term
"stable", as
37
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
used herein, refers to compounds that possess stability sufficient to allow
manufacture,
formulation, and administration to a mammal by methods known in the art.
Typically,
such compounds are stable at a temperature of 40 C or less, in the absence of
moisture or
other chemically reactive conditions, for at least a week. In one embodiment,
the
compounds have less than 5% degradation after storage in the dark at 40 C or
less, in the
absence of moisture or other chemically reactive conditions. In another
embodiment
compounds have less than 10% degradation after storage in the dark at 40 C or
less, in the
absence of moisture or other chemically reactive conditions.
The term "alkyl", alone or in combination with any other term, refers to a
straight-
chain or branched-chain saturated aliphatic hydrocarbon radical containing the
specified
number of carbon atoms, or where no number is specified, advantageously from 1
to about
12 or 1 to 15 carbon atoms. Examples of alkyl radicals include, but are not
limited to:
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl,
pentyl, isoamyl,
n-hexyl and the like.
The term "alkenyl", alone or in combination with any other term, refers to a
straight-chain or branched-chain mono- or poly-unsaturated aliphatic
hydrocarbon radical
containing the specified number of carbon atoms, or where no number is
specified,
advantageously from 2-6 or 2-10 carbon atoms. Alkenyl groups include all
possible E and
Z isomers unless specifically stated otherwise. Examples of alkenyl radicals
include, but
are not limited to, ethenyl, propenyl, isopropenyl, butenyl, isobutenyl,
pentenyl, hexenyl,
hexadienyl and the like.
The term "alkynyl," alone or in combination with any other term, refers to a
straight-chain or branched-chain hydrocarbon radical having one or more triple
bonds
containing the specified number of carbon atoms, or where no number is
specified,
advantageously from 2 to about 10 carbon atoms. Examples of alkynyl radicals
include,
but are not limited to, ethynyl, propynyl, propargyl, butynyl, pentynyl and
the like.
The term "alkoxy" refers to an alkyl ether radical, where the term "alkyl" is
as
defined above. Examples of suitable alkyl ether radicals include, but are not
limited to,
methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-
butoxy and
the like.
The terms "alkylamino" or "dialkylamino" include amino radicals substituted by
one or two alkyl groups, where the term "alkyl" is defined above, and the
alkyl groups can
be the same or different. Examples of suitable alkylamino and dialkylamino
radicals
38
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
include, but are not limited to, methylamino, ethylamino, isopropylamino,
dimethylamino,
methylethylamino, ethylbutylamino and the like.
The term "halo" or "halogen" includes fluorine, chlorine, bromine or iodine.
Halo
may be limited to fluorine, chlorine, and bromine or fluorine and chlorine.
The term "haloalkyl" includes alkyl groups with one or more hydrogens replaced
by halogens.
The term "thioalkyl" includes alkyl radicals having at least one sulfur atom,
where
alkyl has the significance given above. An example of a thioalkyl is CH3SCH2-.
The
definition also encompasses the corresponding sulfoxide and sulfone of this
thioalkyl,
CH3S(0)CH2- and CH3S(0)2CH2- respectively. Unless expressly stated to the
contrary,
the terms "-SO2-" and "-S(0)2-" as used herein include sulfones or sulfone
derivatives (i.e.,
both appended groups linked to the S), and not a sulfinate ester.
The terms "carboalkoxy" or "alkoxycarbonyl" include alkyl esters of a
carboxylic
acid. Examples of "carboalkoxy" or "alkoxycarbonyl" radicals include, but are
not limited
to, ethoxycarbonyl (or carboethoxy), Boc (or t-butoxycarbonyl), Cbz (or
benzyloxycarbonyl) and the like.
The term "alkanoyl" includes acyl radicals derived from an alkanecarboxylic
acid.
Examples of alkanoyl radicals include, but are not limited to acetyl,
propionyl, isobutyryl
and the like.
The term "aryl," alone or in combination with any other term, refers to a
carbocyclic aromatic radical (such as phenyl or naphthyl) containing a
specified number of
carbon atoms. In some embodiments, aryl radicals contain from 6-16 carbon
atoms, and in
other embodiments aryl radicals contain from 6 to 14 or 6-10 carbon atoms in
their ring
structures. Aryl radicals may be optionally substituted with one or more
substituents
selected from alkyl, alkoxy, (for example methoxy), nitro, halo, amino, mono
or
dialkylamino, carboalkoxy, cyano, thioalkyl, alkanoyl, carboxylate, and
hydroxy.
Examples of aryl radicals include, but are not limited to phenyl, p-tolyl, 4-
hydroxyphenyl,
1-naphthyl, 2-naphthyl, indenyl, indanyl, azulenyl, fluorenyl, anthracenyl and
the like.
The term "aralkyl", alone or in combination, includes alkyl radicals as
defined
above in which one or more hydrogen atoms is replaced by an aryl radical as
defined
above. Examples of aralkyl radicals include, but are not limited to benzyl, 2-
phenylethyl
and the like. The alkyl radical of a aralkyl group may be an alkyl radical
having 1 to 4, 1
to 6, 1 to 8, 2 to 4, 2 to 6 or 2 to 8 carbon atoms.
39
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
The tent! "carbocycle" refers to a non-aromatic, stable 3- to 8-membered
carbon
ring which can be saturated, mono-unsaturated or poly-unsaturated. The
carbocycle can be
attached at any endocyclic carbon atom which results in a stable structure. In
some
embodiments, carbocycles having 5-7 carbons may be employed, whereas in other
embodiments carbocycles having 5 or 6 carbon atoms may be employed.
The term "cycloalkyl", alone or in combination, includes alkyl radicals which
contain from about 3 to about 8 carbon atoms and are cyclic. Examples of such
cycloalkyl
radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the
like.
The term "cycloalkenyl" alone or in combination includes alkenyl radicals as
defined above which contain about 3-8 carbon atoms and are cyclic.
In some embodiments of carbocycles, cycloalkyl or cycloalkenyl groups contain
3
or 4 carbon atoms in their ring structure. In other embodiments of
carbocycles, cycloalkyl
or cycloalkenyl groups contain 5 or 6 carbon atoms in their ring structure. In
still other
embodiments of carbocycles, cycloalkyl or cycloalkenyl groups contain 7 or 8
carbon
atoms in their ring structure.
The term "cycloalkylalkyl" includes alkyl radicals as defined above which are
substituted by a cycloalkyl radical containing from about 3 to about 8 carbon
atoms in
some embodiments, or from about 3 to about 6 carbon atoms in other
embodiments.
The term "heterocycly1" or "heterocyclo" or "heterocycloalkyl" refers to a
stable 3-
7 membered monocyclic heterocycle or 8-11 membered bicyclic heterocycle which
is
either saturated or partially unsaturated, and which can be optionally
benzofused if
monocyclic and which is optionally substituted on one or more carbon atoms by
halogen,
alkyl, alkoxy, oxo, and the like, and/or on a secondary nitrogen atom (i.e., -
NH-) by alkyl,
aralkoxycarbonyl, alkanoyl, alkoxycarbonyl, arylsulfonyl, phenyl or
phenylalkyl or on a
tertiary nitrogen atom (i.e., +N-) by oxido and which is attached via a carbon
atom. Each
heterocycle consists of one or more carbon atoms and from one to four
heteroatoms
selected from the group consisting of nitrogen, oxygen and sulfur. As used
herein, the
tent's "nitrogen and sulfur heteroatoms" include oxidized forms of nitrogen
and sulfur, and
the quaternized folin of any basic nitrogen. A heterocyclyl (heterocyclo or
heterocycloalkyl) radical can be attached at any endocyclic carbon or
heteroatom which
results in the creation of a stable structure. In some embodiments, the
heterocycles are 5-7
membered monocyclic heterocycles, and 8-10 membered bicyclic heterocycles.
Examples
of such groups are imidazolinyl, imidazolidinyl, indazolinyl,
perhydropyridazyl,
pyrrolinyl, pyrrolidinyl, piperidinyl, pyrazolinyl, piperazinyl, morpholinyl,
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
thiamorpholinyl, thiazolidinyl, thiamorpholinyl sulfone, oxopiperidinyl,
oxopyrrolidinyl,
oxoazepinyl, tetrahydropyranyl, tetrahydrofuranyl, dioxolyl, dioxinyl,
benzodioxolyl,
dithiolyl, tetrahydrothienyl, sulfolanyl, dioxanyl, dioxolanyl,
tetahydrofurodihydrofuranyl,
tetrahydropyranodihydrofuranyl, dihydropyranyl, tetradyrofurofuranyl and
tetrahydropyranofuranyl.
The term "heteroaryl" refers to stable 5-6 membered monocyclic or 8-11
membered
bicyclic or 13-16 membered tricyclic aromatic heterocycles where heterocycle
is as defined
above. In some embodiments, heteroatoms present in heteroaryl radicals are
limited to one
or more independently selected 0, N or S atoms. Non-limiting examples of such
groups
include imidazolyl, quinolyl, isoquinolyl, indolyl, indazolyl, pyridazyl,
pyridyl, pyrrolyl,
pyrazolyl, pyrazinyl, quinoxalinyl, pyrimidinyl, furyl, thienyl, triazolyl,
thiazolyl,
carbolinyl, tetrazolyl, benzofuranyl, oxazolyl, benzoxazolyl, benzimidazolyl,
benzthiazolyl, isoxazolyl, isothiazolyl, furazanyl, thiadiazyl, acridinyl,
phenanthridinyl,
and benzocinnolinyl.
The term "heterocycloalkylalkyl" refers to an alkyl radical as defined above
which
is substituted by a heterocycloalkyl radical as defined above. The alkyl
radical of a
heterocycloalkylalkyl group may be an alkyl radical having 1 to 4, 1 to 6, 1
to 8, 2 to 4, 2
to 6 or 2 to 8 carbon atoms.
The term "heteroaralkyl" alone or in combination, includes alkyl radicals as
defined
above in which one or more hydrogen atom is replaced by a hetoroaryl group as
defined
above. The alkyl radical of a heteroaralkyl group may be an alkyl radical
having 1 to 4, 1
to 6, 1 to 8, 2 to 4, 2 to 6 or 2 to 8 carbon atoms.
As used herein, the compounds of this technology (e.g., compounds of formula
(I))
are defined to include pharmaceutically acceptable derivatives or prodrugs
thereof. A
"pharmaceutically acceptable derivative or prodrug" includes a
pharmaceutically
acceptable salt, ester, salt of an ester, or other derivative of a compound of
this technology
which, upon administration to a recipient, is capable of providing (directly
or indirectly) a
compound of this technology. In some embodiments it is desirable to employ
derivatives
and prodrugs that increase the bioavailability of the compounds of this
technology when
such compounds are administered to a mammal (e.g., by allowing an orally
administered
compound to be more readily absorbed into the blood) or which enhance delivery
of the
parent compound to a biological compartment (e.g., the brain or lymphatic
system) relative
to the parent species. Examples of prodrugs of hydroxy containing compounds
are amino
acid esters or phosphonate or phosphate esters that can be cleaved in vivo
hydrolytically or
41
CA 02716347 2015-08-18
enzymatically to provide the parent compound. These have the advantage of
providing
potentially improved solubility.
The compounds of this technology (e.g., compounds of formula (I)) can contain
one or more asymmetric carbon atoms and thus occur as racemates and racemic
mixtures,
single enantiomers, diastereomeric mixtures and individual diastereomers. All
such
isomeric forms of these compounds are expressly included in the technology
described
herein. Each stereogenic carbon can be of the R or S configuration. Although
the specific
compounds exemplified in this application can be depicted in a particular
stereochemical
configuration, compounds having either the opposite stereochemistry at any
given chiral
center or mixtures thereof are also envisioned. Thus, the compounds provided
herein may
be enantiomerically pure, or be stereoisomeric or diastereomeric mixtures.
It is also to be understood that the compounds provided herein may have
tautomeric
forms. All such tautomeric forms are included within the scope of the instant
disclosure.
For example, a 3-enamino-2-oxindole where the amino group of the enamine has a
hydrogen substituent has the tautomeric form of a 3-imino-2-hydroxyindole.
Also included in the present application are one or more of the various
polymorphs
of the compounds. A crystalline compound disclosed in the present application
may have
a single or may have multiple polymorphs, and these polymorphs are intended to
be
included as compounds of the present application. Also, where a single
polymorph is
noted, the polymorph may change or interconvert to one or more different
polymorphs, and
such polymorph or polymorph mixtures are included in the present application.
Preparation of Compounds
The compounds described herein can be prepared according to synthetic methods
known in the art set forth, for example, in U.S. Patent No.: 6,319,946 to Hale
et al.,
W02008022345A2 (Eissenstat et al.) and in J.Med.Chem.36: 288-291 (1993),
together with
procedures of the type described below. Reactions and processes for obtaining
the
compounds, particularly the formation of ester and amide linkages, may also be
found in
treatises and text, including, but not limited to, Advanced Organic Synthesis,
4th Edition, J.
March, John Wiley & Sons, 1992 or Protective Groups in Organic Synthesis 3rd
Edition,
T. W. Green & P. G. M. Wuts, John Wiley & Sons, 1999.
The starting materials and reagents used in preparing these compounds are
either
available from commercial suppliers such as Aldrich Chemical Co., (Milwaukee,
Wis.),
42
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
Bachem (Torrance, Calif.), or Sigma (St. Louis, Mo.) or are prepared by
methods known
to those skilled in the art following procedures set forth in references such
as Fieser and
Fieser's Reagents for Organic Syntheses, Volumes 1-85 (John Wiley and Sons);
Rodd's
Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science
Publishers, 1989); Organic Reactions, Volumes 1-71 (John Wiley and Sons),
Advanced
Organic Synthesis, 4th Edition, J. March, John Wiley & Sons, 1992, and
Larock's
Comprehensive Organic Transformations (VCH Publishers Inc., 1989).
Protective groups, such as those described in Protective Groups in Organic
Synthesis 3rd Edition, T. W. Green & P. G. M. Wuts, John Wiley & Sons, 1999
may be
employed for a variety of purposes in the preparation of compounds encompassed
by this
disclosure. They may be employed to control the number or placement of
substituents, or
to protect functionalities that are otherwise unstable to reaction conditions
employed for
the introduction or modification of other substituents in a molecule. Where
employed,
such protective groups may be removed by suitable means. Alternatively, where
the
protective group is desirable in the product they may be introduced and not
removed.
While compounds encompassed by this disclosure may be prepared by a variety of
methods known in the art, they may often be prepared from alpha-amino acids or
the amide
of an alpha-amino acid (alpha-amino acid amide). Whether starting with an
alpha-amino
acid or amide substituents present at RI and R2 may be introduced by
alkylating, acylating
or sulfonylating the amino nitrogen. Where an alpha-amino acid is employed as
a starting
material, reaction of the amino group may be accomplished prior to the
introduction of the
amide nitrogen with or without its pendant R5 and R6 functionalities.
Alternatively, the
amino group may be alkylated, acylated, or sulfonylated subsequent to the
introduction of
the amide nitrogen into the molecule.
Substituents may be introduced into the R3 and R4 positions of the molecule by
a
variety of means. In some embodiments, substituents at R3 and R4 may be
present in
starting amino acids or alpha-amino acid amides. For example, where it is
desirable to
prepare compounds having benzyl substituents at R3 or R4 phenylalaninamide (2-
amino-3-
phenylpropanamide) may be employed as a starting material. The desired
products can be
produced by modification of the nitrogen atom present in the amine and/or
amide of that
compound. In addition, the stereochemistry the benzyl group (or other groups
present in
the starting amino acid) may be controlled by employing a chiral starting
material such
(2S)-2-amino-3-phenylpropanamide, which is available from Sigma-Aldrich.
43
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
Where it is necessary to protect amine functionalities in the synthetic
process they
may be unprotected by suitable reactions. For example, in the formation of
compounds
bearing R1 and R2 substituents where it is necessary to protect the amino
group, Boc
protective groups may be employed, Boc groups may be removed under acidic
conditions,
such as with trifluoroacetic acid, to provide amine functionalities that may
be subject to a
variety of reactions including, but not limited to, condensation with acid
chlorides,
anhydrides, sulfonyl chlorides, chlorofoimates, carbamoyl chloride,
isocyanates and the
like to provide the corresponding amide, sulfonamide, urethane, or urea.
Reductive amination of a primary amine by an aldehyde under acidic conditions,
which provides a secondary amine, can also be employed to prepare substituted
(e.g.,
alkylated) amines. Once the secondary amine is formed it can also be subjected
to
condensation reactions to give the N-alkyl products (e.g., N-alkyl amide). The
substituted
amines can be present at the alpha position of an amino acid or amino acid
amide, in which
case the substituents present on the amine will be the RI and R2 groups or
precursors
thereof. Alternatively, the substituted amine may be reacted with the carboxyl
group to
form an amide functionality, in which case the substituents will be the R5 and
R6 groups or
precursors thereof. Where the carboxyl group is a substituent on an
appropriately
functionalized amino acid, condensation with the substituted amine can result
in the direct
production of compounds within the scope of this disclosure.
As with reductive amination, the reaction of epoxides with amines (e.g.,
isobutylamine) can be employed to form substituted amines. Once formed, such
substituted amines can be employed in the same fashion as the products of
reductive
amination.
By way of example, a benzofuran sulfonyl radical may be added by condensation
of a benzofuransulfonyl chloride (e.g., benzofuran-5-sulfonyl chloride) with
an alpha-
amino acid amide (e.g., the amino nitrogen of NH2-CH2-C(=0)NH2). Alkylation of
the
product can be accomplished using excess base and alkylating agent to produce
compounds within the scope of this disclosure.
Assessment of Compounds
The potency of the compounds can be measured using assays, for example, an in
vitro fluorometric assay. Typically, the ability of a test compound to inhibit
P450 is
assayed by determining the concentration of the test compound required to
decrease the
rate of metabolism of a CYP substrate (also referred to herein as reference
compound) by
half. The CYP substrate can be, for example, dibenzylfluorescein. The ability
of a test
44
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
compound to inhibit the rate of metabolism of a reference compound by half is
known as
the IC50 value. Human liver microsomes can be used for this purpose. Test
compounds
can be diluted with a suitable solvent, such as acetonitrile, in wells of a
micro-titer plate.
Known cytochrome P450 inhibitors such as ritonavir and ketoconazole can be
used as
references. A suitable buffer solution and NADPH or an NADPH generating system
such
as, for example, G6P dehydrogenase can be used. After mixing the inhibitors
with the
buffer and NADPH system, the plates can be incubated for a suitable time at a
suitable
temperature. A solution containing human liver microsomes can be added. A
buffer
containing a fluorogenic substrate, such as dibenzylfluorescein (DBF), can be
added and
the plates allowed to incubate for a suitable time at a suitable temperature.
The IC50 values
for the test compounds can be measured by determining the amount of
fluorescence in each
well and analyzing the values using commercially available software programs
such as, for
example, Grafit (Erithacus Software Ltd., Surrey, U.K.).
Increasing The Half-Life Of Therapeutics By Preventing Their Metabolism By
Cytochrome P450 Enzymes
GYP enzymes are responsible for the metabolic degradation of a variety of drug
molecules (therapeutics). In many instances, those enzymes may largely
determine the
pharmacokinetics observed for drug molecules and control their
bioavailability. Where
GYP enzymes contribute to the metabolism of compounds, compositions that can
inhibit
GYP enzymes can improve the pharmacokinetics and bioavailability of such
drugs.
In certain embodiments, the technology provides methods for inhibiting
cytochrome P450 monooxygenase by administering to a patient one or more
compounds
described herein. The compound can function as a potent cytochrome P450
inhibitor and
can improve the pharmacokinetics of a drug (or a pharmaceutically acceptable
salt thereof)
which is metabolized by cytochrome P450 monooxygenase. The compound or its
pharmaceutically acceptable salt can be administered by itself or in
combination with the
another drug. When administered in combination, the two therapeutic agents
(compound
and drug) can be formulated as separate compositions which are administered at
the same
time or at different times, or the two therapeutic agents can be administered
as a single
composition.
The compounds of the technology are effective for inhibiting a variety of GYP
enzymes. In particular, many of the compounds are highly potent inhibitors of
CYP3A4,
which is responsible for degrading many pharmaceutically important drugs. Use
of the
compounds of the technology therefore permits reduced rates of drug
degradation and
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
consequently extended durations of action in vivo. Consequently, these
compounds are
useful for "boosting" the activities of a variety of drugs, including, but not
limited to, HIV
protease inhibitors by inhibiting CYP3A4-mediated degradation of those
inhibitors.
Drugs which are metabolized by cytochrome P450 monooxygenase and which
benefit from coadministration with a compound of the technology include, but
are not
limited to, the immunosuppressants cyclosporine, FK-506 and rapamycin, the
chemotherapeutic agents taxol and taxotere, the antibiotic clarithromycin and
the HIV
protease inhibitors A-77003, A-80987, indinavir, saquinavir, amprenavir,
nelfinavir,
fosamprenavir, lopinavir, atazanavir, darunavir, tipranavir, DMP-323, XM-450,
BILA
2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629
(N,N-dimethylglycyl-N-(2-hydroxy-3-(((4-methoxyphenyl)sulphonyl)(2-
methylpropyl)amino)-1-(phenylmethyppropy1)-3-methyl-L-valinamide), PPL-100,
SPI-
256 and KNI-272.
In other examples, the drug may be a tyrosine kinase inhibitor, such as
Gleevec
(imatinib), Erlotinib, Sorafenib, Sunitinib, dasitinib, lapatinib, and the
like. Other kinase
inhibitors, such as serine/threonine kinase inhibitors, also may be "boosted."
Suitable
kinase inhibitors for boosting also are described in Ken i et al.; "Signal
Transduction
Therapy with Rationally Designed Kinase Inhibitors," Current Signal
Transduction
Therapy, 1, 67-95 67 (2006). The drug may also be an HSP90 inhibitor such as
geldanamycin, herbimycin, and others, as described by Workman et al.:
"Drugging the
cancer chaperone HSP90: Combinatorial therapeutic exploitation of onco gene
addiction
and tumor stress" Workman, Ann N Y Acad Sci, 1113:202-216 (2007). In other
examples,
the drug may be an inhibitor of HCV NS3 protease, NS4a cofactor, NS4B, N55a
replicase
or NS5B polymerase. Drugs for treating HIV include, in addition to HIV
protease
inhibitors, inhibitors of CD4-gp120 interaction, CCR5 and CRCX4 coreceptors,
and
inhibitors of the LED GF-integrase interaction.
Protease inhibitors and non-nucleoside reverse transcriptase inhibitors
currently
indicated for use in treatment of HIV or HCV are typically good substrates of
cytochrome
p450 enzymes; in particular, they are metabolized by CYP3A4 enzymes (see e.g.,
Sahai,
AIDS 10 Suppl 1:S21-5, 1996) with possible participation by CYP2D6 enzymes
(Kumar et
al., .1 Pharmacol. Exp. Ther. 277(1):423-31, 1996). The compounds described
herein can
block the action and up-regulation of these enzymes, thus reducing the
metabolism of the
protease inhibitors, allowing for lower doses and reduction of sometimes
serious side
effects.
46
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
Some embodiments, described herein are directed to methods for improving the
pharmacokinetics of an HIV protease inhibitor (or a pharmaceutically
acceptable salt
thereof), which is metabolized by cytochrome P450 monooxygenase. Those methods
comprise co-administering to a subject or patient (e.g, a human being) a
compound of the
technology or a pharmaceutically acceptable salt or co-crystal thereof and an
HIV protease
inhibitor. Such a combination of a compound of the technology (e.g., a
compound of
formula (I)), or a pharmaceutically acceptable salt thereof, and an HIV
protease inhibitor,
or a pharmaceutically acceptable salt thereof, which is metabolized by
cytochrome P450
monooxygenase is useful for inhibiting HIV protease in humans. The combination
is also
useful for the inhibition, treatment or prophylaxis of an HIV infection or
AIDS (acquired
immune deficiency syndrome) in humans. When administered in combination, the
two
therapeutic agents can be formulated as separate compositions which are
administered at
the same time or different times, or the two therapeutic agents can be
administered as a
single composition. In some embodiments the HIV protease inhibitors are
selected from
A-77003, A-80987, amprenavir atazanavir, darunavir, fosamprenavir, indinavir,
lopinavir,
nelfinavir, ritonavir, saquinavir, tipranavir, DMP-323, XM-450, BILA 2011 BS,
BILA
1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, (N,N-
dimethylglycyl-N-(2-hydroxy-3-(((4-methoxyphenyl)sulphonyl)(2-
methylpropyl)amino)-
1-(phenylmethyl)propy1)-3-methyl-L-valinamide), PPL-100, SPI-256 or KNI-272.
Methods of Administration
The compounds of the technology can be administered in the form of
pharmaceutically acceptable salts derived from inorganic or organic acids.
Included
among such acid salts, for example, are the following: acetate, adipate,
alginate, aspartate,
benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate,
camphorsulfonate,
cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate,
fumarate,
glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate,
hydrochloride,
hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate,
methanesulfonate,
2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-
phenylpropionate, picrate, pivalate, propionate, succinate, tartrate,
thiocyanate, tosylate and
undecanoate.
Other pharmaceutically acceptable salts include salts with an inorganic base,
organic base, inorganic acid, organic acid, or basic or acidic amino acid.
Inorganic bases
which form pharmaceutically acceptable salts include alkali metals such as
sodium or
47
CA 02716347 2015-08-18
potassium, alkali earth metals such as calcium and magnesium, aluminum, and
ammonia.
Organic bases which form pharmaceutically acceptable salts include
trimethylamine,
triethylamine, pyridine, picoline, ethanolamine, diethanolamine,
triethanolamine,
dicyclohexylamine. Inorganic acids which form pharmaceutically acceptable
salts include
hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric
acid. Organic
acids appropriate to form salts include formic acid, acetic acid,
trifluoroacetic acid, furnaric
acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid,
malic acid,
methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid. Basic
amino acids
used to form salts include arginine, lysine and ornithine. Acidic amino acids
used to form
salts include aspartic acid and glutamic acid.
The CYP inhibitory compounds described herein may be prepared and
administered as a composition comprising a co-crystals with other compounds
(co-crystal
fomers). "Co-crystal" as used herein means a crystalline material comprised of
two or
more unique solids at room temperature, each containing distinctive physical
characteristics, such as structure, melting point and heats of fusion. Co-
crystals are
described, for example, in U.S. Pub, No.: 20070026078 Al.
They are also described in , N. A. Meanwell, Annual Reports in
Medicinal Chemistry, Volume 43, 2008 and D. P. McNamara, Pharmaceutical
Research,
Vol. 23, No. 8, 2006.
The technology also contemplates compositions which can be administered orally
or non-orally in the form of, for example, granules, powders, tablets,
capsules, syrup,
suppositories, injections, emulsions, elixirs, suspensions or solutions, by
mixing these
effective components, individually or simultaneously, with pharmaceutically
acceptable
carriers, excipients, binders, diluents or the like.
As a solid formulation for oral administration, the composition can be in the
form
of powders, granules, tablets, pills and capsules. In these cases, the
compounds can be
mixed with at least one additive, for example, sucrose, lactose, cellulose
sugar, mannitol,
maltitol, dextran, starch, agar, alginates, chitins, chitosans, pectins,
tragacanth gum, gum
arable, gelatins, collagens, casein, albumin, synthetic or semi-synthetic
polymers or
glycerides. These formulations can contain, as in conventional cases, further
additives, for
example, an inactive diluent, a lubricant such as magnesium stearate, a
preservative such as
paraben or sorbic acid, an anti-oxidant such as ascorbic acid, tocopherol or
cysteine, a
disintegrator, a binder, a thickening agent, a buffer, a sweetener, a
flavoring agent and a
perfuming agent. Tablets and pills can further be prepared with enteric
coating.
48
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
Examples of liquid preparations for oral administration include
pharmaceutically
acceptable emulsions, syrups, elixirs, suspensions and solutions, which can
contain an
inactive diluent, for example, water.
As used herein, "non-orally" includes subcutaneous injection, intravenous
injection, intramuscular injection, intraperitoneal injection or instillation.
Injectable
preparations, for example sterile injectable aqueous suspensions or oil
suspensions, can be
prepared by known procedures in the fields concerned, using a suitable
dispersant or
wetting agent and suspending agent. The sterile injections can be, for
example, a solution
or a suspension, which is prepared with a non-toxic diluent administrable non-
orally, such
as an aqueous solution, or with a solvent employable for sterile injection.
Examples of
usable vehicles or acceptable solvents include water, Ringer's solution and an
isotonic
aqueous saline solution. Further, a sterile non-volatile oil can usually be
employed as
solvent or suspending agent. A non-volatile oil and a fatty acid can be used
for this
purpose, including natural or synthetic or semi-synthetic fatty acid oil or
fatty acid, and
natural or synthetic mono- or di- or tri-glycerides.
The pharmaceutical compositions can be formulated for nasal aerosol or
inhalation
and can be prepared as solutions in saline, and benzyl alcohol or other
suitable
preservatives, absorption promoters, fluorocarbons, or solubilizing or
dispersing agents.
Rectal suppositories can be prepared by mixing the drug with a suitable
vehicle, for
example, cocoa butter and polyethylene glycol, where the vehicle is in the
solid state at
ordinary temperatures and in the liquid state at body temperatures, where
melting releases
the drug.
The pharmaceutical composition can be easily formulated for topical
administration
with a suitable ointment containing one or more of the compounds suspended or
dissolved
in a carrier, which include mineral oil, liquid petroleum, white petroleum,
propylene
glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
In
addition, topical formulations can be formulated with a lotion or cream
containing the
active compound suspended or dissolved in a carrier. Suitable carriers include
mineral oil,
sorbitan monostearate, polysorbate 60, cetyl esters wax, cetaryl alcohol, 2-
octyldodecanol,
benzyl alcohol and water.
In some embodiments, the pharmaceutical compositions can include a-, f3-, or y-
cyclodextrins or their derivatives. In certain embodiments, co-solvents such
as alcohols
can improve the solubility and/or the stability of the compounds in
pharmaceutical
49
CA 02716347 2015-08-18
compositions. In the preparation of aqueous compositions, addition salts of
the compounds
can be suitable due to their increased water solubility.
Appropriate cyclodextrins are a-, p-, or 7 -cyclodextrins (CDs) or ethers and
mixed
ethers thereof where one or more of the hydroxy groups of the anhydroglucose
units of the
cyclodextrin are substituted with CI-C6alkyl, such as methyl, ethyl or
isopropyl, e.g.,
randomly methylated 13-CD; hydroxy Cl_oalkyl, particularly hydroxyethyl,
hydroxypropyl
or hydroxybutyl; carboxy Ci-C6alkyl, particularly carboxymethyl or
carboxyethyl; C)-
C6alkyl-carbonyl, particularly acetyl; Ci-C6alkyloxycarbonylCi-C6alkyl or
carboxyCl-
C6alkyloxyC 1-C6alkyl, particularly carboxymethoxypropyl or
carboxyethoxypropyl; C--
C6alkylcarbonyloxyCI-C6alkyl, particularly 2-acetyloxypropyl. Especially
noteworthy as
complexants and/or solubilizers are (3-CD, randomly methylated 13-CD, 2,6-
dimethyl-13-
CD, 2-hydroxyethyl-13-CD, 2-hydroxyethyl-'y-CD, hydroxypropyl-y-CD and (2-
carboxymethoxy)propyl- f3-CD, and in particular 2-hydroxypropyl-fl-CD (2-HP-fl-
CD).
The term "mixed ether" denotes cyclodextrin derivatives where at least two
cyclodextrin hydroxy groups are etherified with different groups such as, for
example,
hydroxypropyl and hydroxyethyl.
The compounds can be formulated in combination with a cyclodextrin or a
derivative thereof as described in US Patent No. 5,707,975. Although the
formulations
described therein are with antifungal active ingredients, they are equally
relevant for
formulating compounds and compositions of the technology described herein
(e.g.,
compounds having the formula (I)). The formulations described therein are
particularly
suitable for oral administration and comprise an antifungal as active
ingredient, a sufficient
amount of a cyclodextrin or a derivative thereof as a solubilizer, an aqueous
acidic medium
as bulk liquid carrier and an alcoholic co-solvent that greatly simplifies the
preparation of
the composition. The formulations can also be rendered more palatable by
adding
pharmaceutically acceptable sweeteners and/or flavors.
Other convenient ways to enhance the solubility of the compounds of the
technology in pharmaceutical compositions are described in WO 94/05263, WO
98/42318,
EP-A-499,299 and WO 97/44014.
In some embodiments, the compounds can be formulated in a pharmaceutical
composition comprising a therapeutically effective amount of particles
consisting of a solid
dispersion comprising a compound of formula I, and one or more
pharmaceutically
acceptable water-soluble polymers.
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
The term "solid dispersion" defines a system in a solid state comprising at
least two
components, where one component is dispersed more or less evenly throughout
the other
component or components. When the dispersion of the components is such that
the system
is chemically and physically uniform or homogenous throughout or consists of
one phase
as defined in thermodynamics, such a solid dispersion is referred to as "a
solid solution".
Solid solutions are one suitable physical system because the components
therein are
usually readily bioavailable to the organisms to which they are administered.
The term "solid dispersion" also comprises dispersions which are less
homogenous
throughout than solid solutions. Such dispersions are not chemically and
physically
uniform throughout or comprise more than one phase.
The water-soluble polymer in the particles is conveniently a polymer that has
an
apparent viscosity of 1 to 100 mPa*s when dissolved in a 2 % aqueous solution
at 20 C.
Water-soluble polymers include hydroxypropyl methylcelluloses (HPMC). HPMC
having a methoxy degree of substitution from about 0.8 to about 2.5 and a
hydroxypropyl
molar substitution from about 0.05 to about 3.0 are generally water soluble.
Methoxy
degree of substitution refers to the average number of methyl ether groups
present per
anhydroglucose unit of the cellulose molecule. Hydroxypropyl molar
substitution refers to
the average number of moles of propylene oxide which have reacted with each
anhydroglucose unit of the cellulose molecule.
The particles as defined hereinabove can be prepared by first preparing a
solid
dispersion of the components, and then optionally grinding or milling that
dispersion.
Various techniques exist for preparing solid dispersions including melt-
extrusion, spray-
drying and solution-evaporation.
It can further be convenient to formulate the compounds in the form of
nanoparticles which have a surface modifier adsorbed on the surface thereof in
an amount
sufficient to maintain an effective average particle size of less than 1000
nm. Useful
surface modifiers are believed to include those which physically adhere to the
surface of
the antiretroviral agent but do not chemically bond to the antiretroviral
agent.
Suitable surface modifiers can preferably be selected from known organic and
inorganic pharmaceutical excipients. Such excipients include various polymers,
low
molecular weight oligomers, natural products and surfactants. Surfactant
surface modifiers
include nonionic and anionic surfactants.
The compounds can also be incorporated in hydrophilic polymers and applied as
a
film over many small beads, thus yielding a composition with good
bioavailability which
51
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
can conveniently be manufactured and which is suitable for preparing
pharmaceutical
dosage forms for oral administration. The beads comprise a central, rounded or
spherical
core, a coating film of a hydrophilic polymer and an antiretroviral agent and
a seal-coating
polymer layer. Materials suitable for use as cores are pharmaceutically
acceptable and
have appropriate dimensions and firmness. Examples of such materials are
polymers,
inorganic substances, organic substances, saccharides and derivatives thereof.
The route of
administration can depend on the condition of the subject, co-medication and
the like.
Dosages of the compounds and compositions described herein are dependent on
age, body weight, general health conditions, sex, diet, dose interval,
administration routes,
excretion rate, combinations of drugs and conditions of the diseases treated,
while taking
these and other necessary factors into consideration. Generally, dosage levels
of between
about 10 lig per day to about 5000 mg per day, preferably between about 25 mg
per day to
about 1000 mg per day of the compounds of the technology are useful for the
inhibition of
CYP enzymes. Typically, the pharmaceutical compositions of this technology
will be
administered from about 1 to about 3 times per day or alternatively, as a
continuous
infusion. Such administration can be used as a chronic or acute therapy.
The amount of active ingredient that can be combined with the carrier
materials to
produce a single dosage form will vary depending upon the host treated and the
particular
mode of administration. A typical preparation will contain from about 5% to
about 95%
active compound (w/w). In some embodiments, such preparations contain from
about 20%
to about 80% active compound.
While these dosage ranges can be adjusted by a necessary unit base for
dividing a
daily dose, as described above, such doses are decided depending on the
diseases to be
treated, conditions of such diseases, the age, body weight, general health
conditions, sex,
diet of the patient then treated, dose intervals, administration routes,
excretion rate, and
combinations of drugs, while taking these and other necessary factors into
consideration.
For example, a typical preparation will contain from about 5% to about 95%
active
compound (w/w). Preferably, such preparations contain from about 10% to about
80%
active compound. The desired unit dose of the composition of this technology
is
administered once or multiple times daily.
In some embodiments, the technology contemplates compositions and formulations
comprising one or more of the compounds in combination with one or more other
drugs
that can be metabolized or degraded by CYP.
52
CA 02716347 2010-08-23
WO 2009/105774
PCT/US2009/034915
The CYP inhibitors of this technology can be administered to a patient either
as a
single agent (for use with a separate dose of another drug) or in a combined
dosage form
with at least one other drug. Additional drugs also can be used to increase
the therapeutic
effect of these compounds.
The compounds of this technology can be administered to patients being treated
with a drug that is metabolized by a CYP enzyme. Such drugs include, but are
not limited
to, anesthetics such as ropivacaine, enflurane, halothane, isoflurane,
methoxyflurane, and
sevoflurane; antiarrhythmics such as mexiletine; antidepressants such as
amitriptyline,
clomipramine, fluvoxamine, bupropion, and imipramine; anti-epileptics such as
diazepam,
phenytoin, S-mephenytoin, and phenobarbitone; antihistamines such as
astemizole,
chlorpheniramine, and terfenadine; antipsychotics such as clozapine,
olanzapine, and
haloperidol; beta blockers such as carvedilol, S-metoprolol, propafenone, and
timolol;
calcium channel blockers such as amlodipine, diltiazem, felodipine,
lercanidipine,
nifedipine, nisoldipine, nitrendipine, and verapamil; hypoglycemic agents such
as
tolbutamide and glipizide; immune modulators such as cyclosporine and
tacrolimus;
muscle relaxants such as cyclobenzaprine, tizanidine, and carisoprodol;
steroids such as
estradiol; antimigraine agents such as zolmitriptan; agents used to treat
breathing aliments
such as zileuton and theophylline; agents used to treat Alzheimer's disease
such as tacrine;
agents used to treat pain such as naproxen and acetaminophen; agents used to
treat
amyotrophic lateral sclerosis such as riluzole; anti-nausea agents such as
ondansetron;
chemotherapeutics such as paclitaxel, ifosfamide, and cyclophosphamide; loop
diuretics
such as torsemide; antidiabetic agents such as repaglinide; statins such as
cerivastatin;
antimalarial agents such as amodiaquine; proton pump inhibitors such as
lansoprazole,
omeprazole, pantoprazole, and rabeprazole; and sulfonylureas such as
glyburide,
glibenclamide, glipizide, glimepiride, and tolbutamide. Patients being treated
with a
protease inhibitor, a reverse transcriptase inhibitor, a viral fusion
inhibitor, or an integrase
inhibitor can also be treated with the compounds provided herein. The CYP
inhibitors
provided herein can be co-administered with the other drug(s). The compounds
of the
technology can also be administered in combination with other cytochrome P450
inhibitors
(e.g., ritonavir), immunomodulators (e.g., bropirimine, anti-human alpha
interferon
antibody, IL-2, interferon alpha, and HE-2000), with antibiotics (e.g.,
pentamidine
isothiorate) cytokines (e.g., Th2), modulators of cytokines, chemokines or the
receptors
thereof (e.g., CCR5) or hormones (e.g., growth hormone) to ameliorate, combat,
or
eliminate infections as therapeutically appropriate.
53
CA 02716347 2015-08-18
CYP inhibitors can also be used as standalone therapeutics for CYP-mediated
diseases, or as prophylactic agents for preventing the production of toxic
metabolites. For
example, an inhibitor of CYP2A6 or 2A13 can be used to ameliorate the
carcinogenic
effects of tobacco usage.
Such combination therapy in different formulations can be administered
simultaneously, separately or sequentially. The CYP inhibitors can be
administered prior
to administration of the other drug to reduce CYP levels and minimize
degradation of the
drug. In specific embodiments, the CYP inhibitor is administered, 30 minutes,
1 hour, four
hours, twelve hours or twenty four hours or more prior to initial
administration of the other
drug. The CYP inhibitors tend to have a long half life in vivo, presumably as
a result of
inhibiting their own metabolism. This means that once treatment has begun, the
CYP
inhibitor may be administered less frequently than the drug, although the
skilled artisan
will recognize that different administration regimens may be needed in
specific situations.
In certain instances, the CYP inhibitor may be administered for a period of
time sufficient
to reduce CYP levels in a subject sufficiently that a drug may be administered
to the
subject without additional dosing of the CYP inhibitor. Similarly, once CYP
levels have
been reduced, administration of the CYP inhibitor may not need to be carried
out as
frequently as administration of the drug. CYP inhibitors also can, in certain
cases, induce
expression of CYPs. The skilled artisan will appreciate that, in such cases,
administration
of the CYP inhibitor may need to be more frequent. Alternatively, such
combinations can
be administered as a single formulation, whereby the active ingredients are
released from
the formulation simultaneously or separately.
The following examples illustrate further the technology.
Examples
Example 1: Assay of IC50 for CYP inhibitors: Determinations using
Dibenzylfluorescein Metabolism by Human Liver Microsomes
A n-licrotiter plate based, fluorometric assay was used for the determination
of the
concentration of a test compound that will decrease by half the rate of
metabolism by
human liver microsomes of dibenzylfluorescein, a CYP3A4 substrate,. The assay
was run
as described by Crespi etal. Anal. Biochem. 248:188-90 (1997).
Test compounds were diluted in acetonitrile in wells of a polypropylene micro-
titer
plate (Denville Scientific, Inc. Metuchen, NJ). Three fold serial dilutions of
the test article
were made from the first well into the next seven wells of a row. Two wells of
each row
54
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
were used for positive controls containing no test compound and two for
negatives
containing 500 M Ritonavir in acetonitrile. Test compounds in acetonitrile
(0.004 mL)
were added to wells of a micro-titer plate (Catalog No. 3598, Corning Costar,
Cambridge,
MA) containing a solution (0.096 mL) of 0.2 M KPO4 Buffer (pH 7.4) and a NADPH
generating system (2.6 mM NADP, 6.6 mM glucose-6-phosphate, 3.3 mM MgCl2 and
0.8
Units/mL G6P dehydrogenase (BD/Gentest, Woburn, MA). The plates were incubated
for
minutes at 37 C. prior to addition of 0.1 mL of pre-warmed 0.1 mg/mL human
liver
microsomes (Xeno Tech, LLC, Lenexa, KS) in 0.2 M KPO4 buffer containing 2 p.M
dibenzylfluorescein (BD/Gentest, Woburn, MA). The plates were incubated for 10
10 minutes at 37 C and the reaction are stopped by the addition of 0.075
mL of 2N NaOH.
Plates were incubated at 37 C for 1 hours prior to determining the amount of
fluorescence
in each well with a fluorescent plate reader (Spectra Max Gemini XS, Molecular
Devices)
at excitation/emission wavelengths of 485 and 538 nm (25 nm), respectively.
Data were
exported and analyzed using GraFite (Erithacus Software Ltd., Surrey, U.K.).
The
background corrected data is fit to a 2-parameter equation for the
determination of the ICso=
Synthetic methods
The following experimental protocols are illustrative of the methods used to
synthesize the compounds of the technology. Syntheses of the compounds below
are
exemplified, although the skilled artisan will recognize that these exemplary
methods are
of general applicability.
Example 2: (S)-2-(benzofuran-5-sulfonamido)-N,N-diisobuty1-3-(pyridin-3-
yl)propanamide (48)
-T
+ HC
el)q
1 4RT N HCl/Doxane 0
OH 3 e 113PTEUA ( 5 )
HN
0 DMF, RI, lh 0 ===,., 2. TEA (3 eq), RT,
30 min
cy--0
0 0 40
0/
0 /
200 c-µ;').0 1
0 48
(1.2 eq), DCM
To a solution of Boc-L-3-(3-pyridyl)alanine (154 mg, 0.58 mmol) in DMF (2 ml)
were added diisobutylamine (0.10 ml, 0.58 mmol), diisopropylethylamine (DIPEA)
(0.30
ml, 1.74 mmol) and 0-(Benzotriazol-1-y1)-N,N,N',N-tetramethyluronium
tetrafluoroborate
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
(TBTU) (330 mg, 0.87 mmol). The mixture was stirred for 1 hr at room
temperature,
quenched with saturated aqueous sodium bicarbonate (15 ml), and extracted with
ethyl
acetate (Et0Ac) (20 m1). The organic phase was washed with brine (15 ml),
dried over
anhydrous MgSO4 and concentrated in vacuo. The crude material was purified by
flash
column chromatography (70% Et0Ac in hexanes) to provide compound 200 (200 mg,
91%) as a white solid. [M+H] 378.3, HPLC purity: >99%.
To a solution of compound 200 (200 mg, 0.53 mmol) in dichloromethane (5 ml)
was added 4N HC1 in dioxane (2 m1). The mixture was stirred for 1 hr at room
temperature
and concentrated in vacuo. To a solution of the resulting material in
dichloromethane (5
ml) were added triethylamine (0.22 ml, 1.6 mmol) and benzofuran-5-sulfonyl
chloride (138
mg, 0.64 mmol). After 30 min, water (10 ml) was added to quench the reaction.
The
aqueous phase was extracted with dichloromethane (5 ml) and the organic layer
was
washed with brine (10 ml), dried over magnesium sulfate and concentrated in
vacuo. The
crude material was purified by preparative TLC (Et0Ac) to provide compound 48
(140
mg, 60%) as a white solid. [M+Hr 458.3, [2M+Nar 937.2, HPLC purity: 97%.
Example 3: Synthesis of Compounds (3), (4), (61), (58), and (80)
The synthesis of compounds 3, 4, 61, 58, and 80 are outlined in the scheme
below.
The individual synthesis of those compounds are described in parts 3a to 3e of
Example 3.
56
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
S
ri ---
N
HN,
1. DIP EA (3 eq), TBTU (1.5 eq) s
diisobutylamine (leg) .*.r
S DMF, RT, 1h 201 S
N rõ 2. 4 N Ha / dioxane OH 1.DIP EA (3 eq),
N N
HN TBTU (1.5 eq),
N, t ____________________________________ vL S-j Nõ
3 AcOH (1 eq), Na0Ac (leg), 00 0 H2N
HO 2 4 N / dioxare 0 ./===.,
0 ,-----õ,
NaBH4 (2 eq), Me0H õ,....-.õ
202
203 /IN 0
N-Boc-L-4-thiazoIyIalanine
\s-J (leg)
TEA (3 eq)
RiCI (1.2 eq) or
TEA (3 eq), DCM DCM
& 0,
Ri0 11 1 2024
C102S W.' / (15 eq)
S
_.. ( "1)N re/)---
-3 ris/>___ N N
,
3)
S N N HN 1( N, NaH (2
eq) R1 0 .,...---.õ
N r` 1 r µ.1 CH3I (1.5 eq)
N,
0 0 ---Sz= 0 ...--...õ
DMF, RI 0õ
4 _______ R1= = 11 ..St- , 58
s-J -- ...õ---...õ , 0
0S:" 00 .
OP 0 / 0
= isi 0)134.
, 3
0 1 0_ 0
61 80
*
= , 4
0 v
Example 3a: Preparation of (S)-N,N-diisobuty1-2-(N-((2-methylthiazol-4-
yl)methyl)benzofuran-5-sulfonamido)-3-(thiazol-4-y1)propanamide (61)
5 To a solution of N-Boc-L-4-thiazolylalanine (100 mg, 0.37 mmol) in
dimethylformamide (DMF) (2 ml) were added diisobutylamine (641x1, 0.37 mmol),
DIPEA
(0.19 ml, 1.10 mmol) and TBTU (180 mg, 0.56 mmol). The mixture was stirred for
1 hr at
room temperature, quenched with saturated aqueous sodium bicarbonate (10 ml),
and
extracted with Et0Ac (10 m1). The organic phase was washed with brine (15 ml),
dried
10 over anhydrous MgSO4and concentrated in vacuo. To a solution of the
resulting material
in dichloromethane (5 ml) was added 4N HC1 in dioxane (2 m1). The mixture was
stirred
for 1 hr at room temperature and concentrated in vacuo. To a solution of the
resulting
compound (104 mg, 0.37 mmol) in methanol (4 ml) were added 2-methy1-1,3-
thiazole-4-
carboxaldehyde (47 mg, 0.37 mmol), acetic acid (21 ul , 0.37 mmol) and sodium
acetate
15 (30 mg,
0.37 mmol). The mixture was stirred for 30 min at room temperature and then
treated with sodium borohydride (28 mg, 0.74 mmol). After 1 hr, saturated
aqueous
sodium bicarbonate (5 ml) was added to quench the reaction. The aqueous phase
was
57
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
extracted with Et0Ac (15 ml) and the organic layer was washed with brine (10
ml), dried
over anhydrous MgSO4and concentrated in vacuo. To a solution of compound 203
in
dichloromethane (10 ml) were added triethylamine (150 p1, 1.11 mmol) and
benzofuran-5-
sulfonyl chloride (120 mg, 0.56 mmol). After 30 min, water (10 ml) was added
to quench
the reaction. The aqueous phase was extracted with dichloromethane (5 ml) and
the
organic layer was washed with brine (10 ml), dried over anhydrous MgSO4 and
concentrated in vacuo. The crude material was purified by preparative TLC (10%
Me0H
in dichloromethane) to provide compound 61(47 mg, 22%) as a colorless oil.
[M+H]
575.0, HPLC purity: >99%.
Example 3b: Preparation of (S)-2-(benzofuran-5-sulfonamido)-N-isobutyl-N-
((2-methylthiazol-4-yl)methyl)-3-(thiazol-4-y1)propanamide (58)
To a solution of commercially available 2-methyl-1,3-thiazole-4-carboxaldehyde
(102 mg, 0.80 mmol) in Me0H (4 ml) were added isobutylamine (0.16 ml, 1.6
mmol),
acetic acid (50 p.1, 0.88 mmol) and sodium acetate (72 mg, 0.88 mmol). The
mixture was
stirred for 30 min at room temperature and treated with sodium borohydride (61
mg, 1.6
mmol). After 30 min, aqueous sodium bicarbonate (8 ml) was added to quench the
reaction. The water phase was extracted with ethyl acetate (10 ml) and the
organic layer
was washed with brine (10 ml) and dried with magnesium sulfate and
concentrated in
vacuo. The crude material was purified by preparative TLC (10% Me0H in
dichloromethane) to provide compound 201 (68 mg, 46%) as a colorless oil.
[M+Hr
185.0, HPLC purity: >99%.
To a solution of N-Boc-L-4-thiazolylalanine (100 mg, 0.37 mmol) in DMF (2 ml)
were added compound 201 (68 mg, 0.37 mmol), DIPEA (0.19 ml, 1.10 mmol) and
TBTU
(178 mg, 0.56 mmol). The mixture was stirred for 1 hr at room temperature,
quenched
with saturated aqueous sodium bicarbonate (10 ml), and extracted with Et0Ac
(10 m1).
The organic phase was washed with brine (15 ml), dried over anhydrous MgSO4and
concentrated in vacuo.
To a solution of the resulting material in dichloromethane (5 ml) was added 4N
HC1 in dioxane (2 m1). The mixture was stirred for 1 hr at room temperature
and
concentrated in vacuo to provide compound 202. To a solution of compound 202
in
dichloromethane (5 ml) were added triethylamine (0.15 ml, 1.1 mmol) and
benzofuran-5-
sulfonyl chloride (129 mg, 0.56 mmol). After 30 min, water (10 ml) was added
to quench
the reaction. The aqueous phase was extracted with dichloromethane (5 ml) and
the
58
CA 02716347 2010-08-23
WO 2009/105774
PCT/US2009/034915
organic layer was washed with brine (10 ml), dried over magnesium sulfate and
concentrated in vacuo. The crude material was purified by preparative TLC
(Et0Ac) to
provide compound 58 (46 mg, 70%) as a white solid. [M+H] 519.0, [M+Nar 541.0,
HPLC purity: 99%.
Example 3c: Preparation of (S)-N-isobuty1-2-(N-methylbenzofuran-5-
sulfonamido)-N-((2-methylthiazol-4-yl)methyl)-3-(thiazol-4-y1)propanamide
(80)
To a solution of compound 58 (76 mg, 0.15 mmol) in DMF (1 ml) were added
sodium hydride (12 mg, 0.30 mmol) and iodomethane (14 ui, 0.23 mmol). After 1
hr,
water (7 ml) was added to quench the reaction. The aqueous phase was extracted
with
Et0Ac (10 ml) and the organic layer was washed with brine (5 ml), dried over
anhydrous
MgSO4 and concentrated in vacuo. The crude material was purified by
preparative TLC
(Et0Ac) to provide compound 80 (49 mg, 61%) as an oil. [M+Hr 533.0, HPLC
purity:
>99%.
Example 3d: Preparation of (S)-benzofuran-5-ylmethyl 1-(isobuty102-
methylthiazol-4-yl)methypamino)-1-oxo-3-(thiazol-4-yl)propan-2-ylcarbamate
(3)
To a solution of benzofuran-5-ylmethanol (503 mg, 3.40 mmol) in
dichloromethane
(8 ml) were added triethylamine (0.71 ml, 5.1 mmol) and bis(4-
nitrophenyl)carbonate (1.0
g, 3.4 mmol). After 1 hr, water (10 ml) was added to quench the reaction. The
aqueous
phase was extracted with dichloromethane (5 ml) and the organic layer was
washed with
brine (10 ml), dried over magnesium sulfate and then concentrated in vacuo.
The crude
material was purified by flash column chromatography (70% Et0Ac in hexanes) to
provide
compound 204 (920 mg, 86%) as a white solid. [M+Hr 314.0, HPLC purity: >99%.
To a solution of compound 202 (45 mg, 0.13 mmol) in dichloromethane (5 ml)
were added DIPEA (45 jil, 0.26 mmol) and compound 204 (41 mg, 0.13 mmol).
After 30
min, the mixture was concentrated in vacuo. The crude material was purified by
preparative HPLC to provide compound 3 (33 mg, 50%) as a colorless oil. [M+H]
513.0,
HPLC purity: >99%.
Example 3e: Preparation of (S)-N-(1-(isobuty1((2-methylthiazol-4-
yl)methyl)amino)-1-oxo-3-(thiazol-4-yl)propan-2-yl)benzofuran-5-
carboxamide (4)
59
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
To a solution of compound 202 (33 mg, 0.097 mmol) in dichloromethane (4 ml)
were added triethylamine (41 p1, 0.29 mmol) and benzofuran-5-carbonyl chloride
(21 mg,
0.12mmol). After 30 min, the mixture was concentrated in vacuo. The crude
material was
purified by preparative TLC (Et0Ac) to provide compound 4 (30 mg, 64%) as a
colorless
oil. [M+H] 483.0, HPLC purity: >98%.
Example 4: Synthesis of Compounds (17), (69), and (79)
The synthesis of compounds 17, 69, and 79 are outlined in the scheme below.
The
individual synthesis of those compounds are described in parts 4a to 4c of
Example 4.
H2N
=+
1. AcOH (1 eq), Na0Ac (1 eq), Me0H, 30 min, rt
, 2. NaBH4 (2 eq), 1 h, rt
N
OH
DIPEA (3 eq) r\ 1. 4 N HCl/Doxane N
TBTU (1.5 eq) N RT, 1h N
____________________________________________________________________ HN
HN H
o 0 DMF, RT, 1h 0 2. TEA (3 eq) o
0 0 0 tert-butylacetyl
chloride
/ (1.2 eq), DCM,
0 / 0 RT, 30 min
69
N-Boc-L-His(3-Me)-OH 205 17
1. DIPEA (1.5 eq), TBTU (1.5 eq)
diisobutylamine (1 eq)
DMF, RT, 1h
2. 4 N HCI / dioxane
3 AcOH (1 eq), Na(0Ac)3BH (2 eq)
DCE
11, CHO (1 eq)
/1--N
NAr. TEA (3 eq)
acetyl chloride (1.2 eq) 110
DCM 0
0
206
79
Example 4a: Preparation of (S)-tert-butyl 1-((benzofuran-5-
ylmethyl)(isobutyl)amino)-3-(1-methyl-1H-imidazol-5-y1)-1-oxopropan-2-
ylcarbamate (17)
To a solution of benzofuran-5-yl-methylamine (212 mg, 1.44 mmol) in Me0H (8
ml) were added isobutyraldehyde (131 1.31, 1.44 mmol), acetic acid (82 1,
1.44 mmol) and
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
sodium acetate (118 mg, 1.44 mmol). The mixture was stirred for 30 min at room
temperature and treated with sodium borohydride (109 mg, 2.88 mmol). After 1
hr,
aqueous sodium bicarbonate (10 ml) was added to quench the reaction. The
aqueous phase
was extracted with Et0Ac (15 ml) and the organic layer was washed with brine
(10 ml),
dried over anhydrous MgSO4 and concentrated in vacua. The crude material was
purified
by preparative TLC (10% Me0H in dichloromethane) to provide compound 205 (260
mg,
89 %) as a white solid. [M+Hr 204.0, HPLC purity: >99%.
To a solution of Boc-His(3-Me)-OH (200 mg, 0.74 mmol) in DMF (8 ml) were
added compound 205 (150 mg, 0.74 mmol), DIPEA (387 1, 2.20 mmol), and TBTU
(356
mg, 1.11 mmol). The mixture was stirred for 1 hr at room temperature, quenched
with
saturated aqueous sodium bicarbonate (10 ml), and extracted with Et0Ac (10
m1). The
organic phase was washed with brine (10 ml), dried over anhydrous MgSO4 and
concentrated in vacua. The crude material was purified by preparative TLC (10%
Me0H
in dichloromethane) to provide compound 17 (320 mg, 95 %) as a yellowish oil.
[M+H]
455.3, purity: 97%.
Example 4b: Preparation of (S)-N-(1-((benzofuran-5-
ylmethyl)(isobutyl)amino)-3-(1-methyl-1H-imidazol-5-y1)-1-oxopropan-2-y1)-
3,3-dimethylbutanamide (69)
To a solution of compound 17 (320 mg, 0.70 mmol) in dichloromethane (4 ml) was
added
4N HC1 in dioxane (4 m1). The mixture was stirred for 1 hr at room temperature
and
concentrated in vacua. To a solution of the resulting material were added
triethylamine
(293 I, 0.49 mmol) and tert-butylacetyl chloride (117 1, 0.84 mmol). After
30 min, water
(10 ml) was added to quench the reaction. The aqueous phase was extracted with
dichloromethane (5 ml) and the organic layer was washed with brine (10 ml),
dried over
anhydrous MgS0.4and concentrated in vacua. The crude material was purified by
preparative TLC (10% Me0H in dichloromethane) to provide compound 69 (220 mg,
70%) as a white solid. [M+Hr 453.3, HPLC purity: 99%.
Example 4c: Preparation of (S)-2-(N-(benzofuran-5-ylmethyl)acetamido)-N,N-
diisobuty1-3-(1-methy1-1H-imidazol-5-y1)propanamide (79)
To a solution of Boc-His(3-Me)-OH (543 mg, 1.86 mmol) in DMF (2 ml) were
added diisobutylamine (320 1, 1.86 mmol), DIPEA (430 p1, 2.79 mmol) and TBTU
(900
mg, 2.79 mmol). The mixture was stirred for 1 hr at room temperature, quenched
with
saturated aqueous sodium bicarbonate (10 ml), and extracted with Et0Ac (10
m1). The
61
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
organic phase was washed with brine (15 ml), dried over anhydrous MgSO4 and
concentrated in vacuo. To a solution of the resulting material in
dichloromethane (5 ml)
was added 4N HC1 in dioxane (4 m1). The mixture was stirred for 1 hr at room
temperature
and concentrated in vacuo. To a solution of the resulting material (204 mg,
0.73 mmol) in
1,2-dichloroethane (10 ml) were added benzofuran-5-carbaldehyde (107 mg, 0.73
mmol)
and acetic acid (42 ui, 0.73 mmol). The mixture was stirred for 30 min at room
temperature and then treated with Na(0Ac)313H (309 mg, 1.46 mmol). After 1 hr,
saturated aqueous sodium bicarbonate (10 ml) was added to quench the reaction.
The
aqueous phase was extracted with Et0Ac (15 ml) and the organic layer was
washed with
brine (10 ml), dried over anhydrous MgSO4 and concentrated in vacuo. To a
solution of
the resulting compound 206 (24 mg, 0.060 mmol) in dichloromethane (4 ml) were
added
triethylamine (24 ul, 0.17 mmol) and acetyl chloride (5 iil, 0.07 mmol). After
30 min, the
mixture was concentrated in vacuo. The crude material was purified by
preparative HPLC
to provide compound 79 (8.0 mg, 28%) as a colorless oil. [M+H] 453.3, HPLC
purity:
>99%.
Example 5: Synthesis of Compounds (42) and (37)
The synthesis of compounds 42 and 37 are outlined in the scheme below. The
individual synthesis of those compounds are described in parts 5a and 5b of
Example 5.
62
CA 02716347 2010-08-23
WO 2009/105774
PCT/US2009/034915
r.
N
OBn OBn ,N
1 LION in water (6 eq) li..,=/-- 0
H1-0H4.. NH DMF, RT, 1h N, . THF / Me0H
0 ________________________________________ k HN
2. DIPEA (3 eq) r
HINiflili-N`
0 0 0 0 TBTU (1.5 eq) o,io
o
.7---, .----,.. Di-(2-
picotylamine)
DMF, RI, 1h .."..
N-Boc-L-Aap(BzI)-OH 207 208
1. LiOH in water (6 eq)
THF / Me0H
rlfµi
2. DIPEA (3 eq)
TBTU (1.5 eq)
3-pyridylcarbinoI
t,
1.4 N HCI / dioxane N
HNr, 0
2. TEA (3 eq) -, 0
0" '0
II 40 0 o
/ -
1. 4 N HCI / dioxane HN
0),,)(C
C102S 41149F __________________________________________________ ,
-S, 0 .=-=..õ
0' '0
DCM o / Htr'f\i'= 2. TEA (3 eq)
S,.o 0 0i
o32,9N505s . 605.75
C iii /102S 41IFI
0 /
.
42 DCM
209 37
C26H33N306
S= 515.62
Example 5a: Preparation of (S)-2-(benzofuran-5-sulfonamido)-N1,N1-
diisobutyl-N4,N4-bis(pyridin-2-ylmethyl)succinamide (42)
To a solution of Boc-L-Asp(Bz1)-OH (1.0 g, 3.1 mmol) in DMF (4 ml) were added
the diisobutylamine (0.54 ml, 3.1 mmol), DIPEA (1.6 ml, 9.3 mmol) and TBTU
(1.5 g, 4.7
mmol). The mixture was stirred for 1 hr at room temperature, quenched with
saturated
aqueous sodium bicarbonate (10 ml), and extracted with Et0Ac (10 m1). The
organic phase
was washed with brine (10 ml), dried over anhydrous MgSO4 and concentrated in
vacuo.
The crude material was purified by flash column chromatography (30% Et0Ac in
hexanes)
to provide compound 207 (1.3 g, 100%) as a white solid. [M+11]+ 435.2, [M+Nar
457.2,
[2M+Na] 891.5, HPLC purity: 99%.
To a solution of compound 207 (490 mg, 1.10 mmol) in tetrahydrofuran/Me0H
(3:1, 8 ml) was added lithium hydroxide in water (2.5M, 2.6 ml, 6.6 mmol). The
mixture
was stirred for 3 hrs at room temperature, quenched with aqueous 1N HCl (10
ml), and
extracted with Et0Ac (10 m1). The organic phase was washed with brine (10 ml),
dried
over anhydrous MgSO4 and concentrated in vacuo. The crude material was
purified by
flash column chromatography to provide (S)-3-(tert-butoxycarbonylamino)-4-
6 3
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
(diisobutylamino)-4-oxobutanoic acid (176 mg, 46%) as an oil. [M+Hr 345.2,
HPLC
purity: >99%.
To a solution of (S)-3-(tert-butoxycarbonylamino)-4-(diisobutylamino)-4-
oxobutanoic acid (176 mg, 0.51 mmol) in DMF (1 ml) were added di-2-
picolylamine (92
pi, 0.51 mmol), DIPEA (0.27 ml, 1.5 mmol), and TBTU (290 mg, 0.77 mmol). The
mixture was stirred for 1 hr at room temperature, quenched with saturated
aqueous sodium
bicarbonate (7 ml) and extracted with Et0Ac (7 m1). The organic phase was
washed with
brine (10 ml), dried over anhydrous MgSO4 and then concentrated in vacuo. The
residue
was purified by preparative TLC (Et0Ac) to provide compound 208 (110 mg, 41%)
as an
oil. [M+H] 526.2, [M+Nar 548.3, HPLC purity: 99%.
To a solution of compound 208 (110 mg, 0.21 mmol) in dichloromethane (2 ml)
was added 4N HC1 in dioxane (1 m1). The mixture was stirred for 1 hr at room
temperature
and concentrated in vacuo. To a solution of the resulting material in
dichloromethane (4
ml) were added triethylamine (88111, 0.63 mmol) and benzofuran-5-sulfonyl
chloride (68
mg, 0.32 mmol). After 30 min, water (5 ml) was added to quench the reaction.
The
aqueous phase was extracted with dichloromethane (5 ml) and the organic layer
was
washed with brine (5 ml), dried over anhydrous MgSO4and concentrated in vacuo.
The
crude material was purified by preparative TLC (10% dichloromethane in Me0H)
to
provide compound 42 (97 mg, 76%) as a colorless oil. [M+H] 606.2, HPLC purity:
99%.
Example 5b: Preparation of (S)-pyridin-3-ylmethyl 3-(benzofuran-5-
sulfonamido)-4-(diisobutylamino)-4-oxobutanoate (37)
To a solution of (S)-3-(tert-butoxycarbonylamino)-4-(diisobutylamino)-4-
oxobutanoic acid (104 mg, 0.30 mmol) in dichloromethane (8 ml) were added 1-
ethyl-3-
{3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) (58 mg, 0.30 mmol),
triethylamine (42 1.11, 0.30 mmol), 3-pyridylcarbinol (34 1, 0.30 mmol) and a
catalytic
amount of 4-dimethylaminopyridine (DMAP) (10 mg) The mixture was stirred for 3
hrs at
room temperature, quenched with water (10 ml), and extracted with
dichloromethane (10
m1). The organic phase was washed with brine (10 ml), dried over anhydrous
MgSO4 and
concentrated in vacuo. The crude material was purified by preparative TLC (50%
Et0Ac
in hexanes) to provide compound 209 (80 mg, 60%) as a colorless oil. [M+H]
436.2,
[M+Nar 458.3, [2M+Nar 893.5, HPLC purity: 99%.
64
CA 02716347 2010-08-23
WO 2009/105774
PCT/US2009/034915
To a solution of compound 209 (80 mg, 0.18 mmol) in dichloromethane (2 ml) was
added 4N HC1 in dioxane (1 m1). The mixture was stirred for 1 hr at room
temperature and
concentrated in vacua. To a solution of the resulting material in
dichloromethane (4 ml)
were added triethylamine (75 I, 0.54 mmol) and benzofuran-5-sulfonyl chloride
(58 mg,
0.27 mmol). After 30 min, water (5 ml) was added to quench the reaction. The
aqueous
phase was extracted with dichloromethane (5 ml) and the organic layer was
washed with
brine (5 ml), dried over anhydrous MgSO4 and then concentrated in vacuo. The
crude
material was purified by preparative HPLC to provide compound 37 (36 mg, 39%)
as a
colorless oil. [M+H] 516.3, [2M+Na] 1053.3, HPLC purity: >99%.
Example 6: Synthesis of Compounds (13) and (67)
The synthesis of compounds 13 and 67 are outlined in the scheme below. The
individual synthesis of those compounds are described in parts 6a and 6b of
Example 6.
HN
OBn
OBn
0 DIPEA (3 eq)
HI\11"TrOH 0 / TBTU (1.5 eq) HNYN
1. 4 N HCI / dioxane
o 0
0 00
DMF, RI, lb 2. Et3N (3 eq)
tert-butylacetyl
0 chloride
(1.5 eq)
N-Boc-L-Aap(BzI)-OH 13 CH2Cl2
I
OBn OH EDC (1.5 eq)
0 water (6 eq)
0 Et3N(3 eq)
DMAP (cat.), DCM, RI 0
111.11,N
A o A o
o 0
0 Ao 0
0
210 220 67
15 Example 6a: Preparation of (5)-tert-butyl 1-((benzofuran-5-
ylmethyl)(isobutyl)amino)-1,4-dioxo-5-phenylpentan-2-ylcarbamate (13)
To a solution of N-Boc-L-Asp(Bz1)-OH (576 mg, 1.78 mmol) in DMF (8 ml) were
added compound 11 (160mg, 0.79 mmol), DIPEA (744 I, 5.34 mmol), and TBTU (857
mg, 2.67 mmol). The mixture was stirred for 1 hr at room temperature, quenched
with
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
saturated aqueous sodium bicarbonate (10 ml), and extracted with Et0Ac (10
m1). The
organic phase was washed with brine (10 ml), dried over anhydrous MgSO4 and
then
concentrated in vacuo. The crude material was purified by flash column
chromatography
(50% Et0Ac in hexanes) to provide compound 13 (395 mg, 97%) as an colorless
oil.
[M+Hr 509.2, HPLC purity: >99%.
Example 6b: Preparation of Synthesis of (S)-pyridin-3-ylmethyl 4-
((benzofuran-5-ylmethyl)(isobutyl)amino)-3-(3,3-dimethylbutanamido)-4-
oxobutanoate (67)
To a solution of compound 13 (395 mg, 0.77 mmol) in dichloromethane (4 ml) was
added 4N HC1 in dioxane (4 m1). The mixture was stirred for 1 hr at room
temperature and
concentrated in vacuo. To a solution of the resulting material in
dichloromethane (8 ml)
were added triethylamine (321 j.il, 2.3 mmol) and tert-butylacetyl chloride
(161 1.11, 1.16
mmol). After 30 mm, water (5 ml) was added to quench the reaction. The aqueous
phase
was extracted with dichloromethane (8 ml) and the organic layer was washed
with brine (8
ml), dried over anhydrous MgSO4 and then concentrated in vacuo. The residue
was
purified by preparative TLC (30% Et0Ac in hexanes) to provide compound 210
(273 mg,
70%) as a colorless oil. [M+H] 507.2, HPLC purity: >99%.
To a solution of compound 210 (273 mg, 70%) in tetrahydrofuran/Me0H (3:1, 16
ml) was added lithium hydroxide in water (2.5M, 1.3 ml, 3.2 mmol). The mixture
was
stirred for 3 hrs at room temperature, quenched with 1N HC1 (10 ml), and
extracted with
Et0Ac (10 m1). The organic phase was washed with brine (10 ml), dried over
anhydrous
MgSO4 and then concentrated in vacuo. The crude material was purified by
preparative
TLC (20% dichloromethane in Me0H) to provide compound 220 (195 mg, 87%) as a
white solid. [M+Hr 417.3, HPLC purity: 99%.
To a solution of compound 220 (95 mg, 0.22 mmol) in dichloromethane (8 ml)
were added EDC (63 mg, 0.33 mmol), triethylamine (92 1, 0.66 mmol), 3-
pyridylcarbinol
(21 mg, 0.22 mmol) and a catalytic amount of DMAP (10 mg). The mixture was
stirred
for 3 hrs at room temperature, quenched with water (10 ml), and extracted with
dichloromethane (10 m1). The organic phase was washed with brine (10 ml),
dried over
anhydrous MgSO4 and concentrated in vacuo. The crude material was purified by
preparative TLC (Et0Ac) to provide compound 67 (30 mg, 27%) as a colorless
oil.
[M+.111+ 508.3, HPLC purity: 99%.
66
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
Example 7: Synthesis of Compounds (33) and (34)
The synthesis of compounds 33 and 34 are outlined in the scheme below. The
individual synthesis of those compounds are described in parts 7a and 7b of
Example 7.
NHFmoc
DIPEA (3 eq)
TBTU (1.5 eq) NHFmoc
NH
diisobutylamine 1. piperidine / AcCN (1:5)
DMF, RT, lh H 2. DIPEA (3 eq)
o 0 TBTU (1.5 eq) 0
o DMF, RT, 1h H
0
,N o
-4;
221
(1 eq)
HO
N-Boc-Lys(Fmoc)-OH
222
1. piperidine / AcCN (1: 5)
2. Na2CO3 (5eq),AcCN Nr--"\r_icI
1.4 N HCI / dioxane
100 C 'N.N1 (2 eq)
2. TEA (3 eq)
3. 4 N HCI / dioxane
a 0, (1.2 ec
4. TEA (3 eq), DCM CIO2S
la 0/
DCM
CIO2S (1.2 eq)
*Al, a
,
HN N
0' 00
o o
34 33
5
Example 7a: Preparation of (S)-2-(benzofuran-5-sulfonamido)-N,N-diisobuty1-
6-(2-(pyridin-3-yl)acetamido)hexanamide (33)
Compound 221 was prepared following the procedure for Scheme 1 except that
instead of Boc-L-3-pyridylalanine Boc-L-Lys(Fmoc)-OH was used as the starting
material.
10 Compound 221 (500 mg, 0.86 mmol) in 20% piperidine in acetonitrile (8
ml) was stirred
for 1 hr at room temperature and concentrated in vacua. To a solution of the
resulting
material in DMF (2 ml) were added the 3-pyridylacetic acid (49 mg, 0.28 mmol),
DIPEA
(0.15 ml, 0.84 mmol) and TBTU (135 mg, 0.42 mmol). The mixture was stirred for
1 hr at
room temperature, quenched with saturated aqueous sodium bicarbonate (10 ml)
and
15 extracted with Et0Ac (10 ml). The organic phase was washed with brine
(10 ml), dried
over anhydrous MgSO4 and concentrated in vacuo. The crude material was
purified by
67
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
preparative TLC (10 % dichloromethane in Me0H) to provide compound 222 (80 mg,
81%) as a yellowish oil. [M+Hr 477.2, HPLC purity: 99%.
To a solution of compound 222 (80 mg, 0.17 mmol) in dichloromethane (4 ml) was
added 4N HC1 in dioxane (4 m1). The mixture was stirred for 1 hr at room
temperature and
concentrated in vacuo. To a solution of the resulting material in
dichloromethane (10 ml)
was added triethylamine (71 tl, 0.51 mmol) and benzofuran-5-sulfonyl chloride
(55 mg,
0.26 mmol). After 30 min, water (5 ml) was added to quench the reaction. The
aqueous
phase was extracted with dichloromethane (5 ml) and the organic layer was
washed with
brine (5 ml), dried over anhydrous MgSO4 and concentrated in vacuo. The crude
material
was purified by preparative TLC (10% dichloromethane in Me0H) to provide
compound
33 (65 mg, 67%) as a white solid. [M+Hr 557.3, HPLC purity: 99%.
Example 7b: Preparation of (S)-2-(benzofuran-5-sulfonamido)-6-(bis((1,5-
dimethy1-1H-pyrazol-3-yl)methyl)amino)-N,N-diisobutylhexanamide (34)
A solution of compound 221 (30 mg, 0.083 mmol) in 20% piperidine in
acetonitrile (2 ml)
was stirred for 1 hr at room temperature and concentrated in vacuo. To a
solution of the
resulting material in acetonitrile (8 ml) were added sodium bicarbonate (16
mg, 0.19
mmol) and 3-(chloromethyl)-1,5-dimethy1-1H-pyrazole (24 mg, 0.17 mmol). The
resulting
mixture was stirred for 2 days at 100 'C. The mixture was quenched with water
(5 ml), and
extracted with Et0Ac (8 m1). The organic phase was dried over anhydrous
MgSO4and
concentrated in vacuo. To a solution of the resulting material in
dichloromethane (4 ml)
was added 4N HC1 in dioxane (4 m1). The mixture was stirred for 1 hr at room
temperature and concentrated in vacuo. To a solution of the resulting material
in
dichloromethane (4 ml) was added triethylamine (35u1, 0.25 mmol) and
benzofuran-5-
sulfonyl chloride (27 mg, 0.12 mmol). After 30 min, water (5 ml) was added to
quench the
reaction. The aqueous phase was extracted with dichloromethane (5 ml) and the
organic
layer was washed with brine (5 ml), dried over anhydrous MgSO4and concentrated
in
vacuo. The crude material was purified by preparative TLC (10% dichloromethane
in
Me0H) to provide compound 34 (33 mg, 60%) as an oil. [M+Hr. 654.3, HPLC
purity:
99%.
68
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
Example 8: Synthesis of Compounds (81), (82) and (83)
The synthesis of compounds 81 82 and 83 are outlined in the scheme below. The
individual synthesis of those compounds are described in parts 8a, 8b and 8c
of Example 8.
NH2
NHBoc NHBoc
DIPEA (3 eq)
TBTU (1.5 eq)
diisobutylamine (1 eq)
1. 10% Pd/C H2 w
BzCHN),y0H DMF, RT, 1h
0
BzCHN 2. TEA (3 eq) o0- '0
o 0
Z-Lys(Boc)-OH 223
C102S 101 224
DCM \ 0
3. 4 N HCI in dioxane, DCM TEA (3 eq)
Acetyl chloi
DCM
0
tiq
NH
TEA (3 eq)
1. AcOH (2 eq),
Na0Ac (2 eq), 'µNH RiCI (1.2 eq)
DCM
p
) ____________ eq)
o
o- -0
Nl N"
2. Na8I-14 (2 eq) HFI HN y
Me0H
0S.0 0 o 40
0- -0
\ 0
0 225 \ 81
0
= Acetyl, 82
= Methanesulfonyl, 83
Example 8a: Preparation of (S)-6-acetamido-2-(benzofuran-5-sulfonamido)-
N,N-diisobutylhexanamide (81)
To a solution of Z-Lys(Boc)-OH (1.0 g, 2.6 mmol) in DMF (8 ml) were added
diisobutylamine (0.46 ml, 2.6 mmol), DIPEA (1.4 ml, 7.8 mmol), and TBTU (1.2
g, 3.9
mmol). The mixture was stirred for 1 hr at room temperature, quenched with
saturated
aqueous sodium bicarbonate (20 ml), and extracted with Et0Ac (20 m1). The
organic
phase was washed with brine (15 ml), dried over anhydrous MgSO4 and
concentrated in
vacuo. The crude material was purified by flash column chromatography (50%
Et0Ac in
hexanes) to provide compound 223 (1.0 g, 80%) as an oil. [M+H] 492.3, HPLC
purity:
99%.
69
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
To a solution of compound 223 (300 mg, 0.61 mmol) in 20%
dichloromethane/Me0H (30 ml) was added 10% Pd/C (30 mg). The mixture was
hydrogenated for 3 hrs at room temperature, filtered through Celite and
concentrated in
vacuo. To a solution of the resulting material in dichloromethane (8 ml) were
added
triethylamine (0.25 ml, 1.83 mmol) and benzofuran-5-sulfonyl chloride (159 mg,
0.73
mmol). After 30 min, water (10 ml) was added to quench the reaction. The
aqueous phase
was extracted with dichloromethane (5 ml) and the organic layer was washed
with brine
(10 ml), dried over anhydrous MgSO4 and concentrated in vacuo. To a solution
of the
resulting material in dichloromethane (8 ml) was added 4N HC1 in dioxane (4
m1). The
mixture was stirred for 1 hr at room temperature and concentrated in vacuo.
The crude
material was purified by preparative TLC (10% dichloromethane in Me0H) to
provide
compound 224 (150 mg, 56%) as a white solid. [M+H] 438.3, [2M+Nar 875.3, HPLC
purity: 99%.
To a solution of compound 224 (150 mg, 0.34 mmol) in dichloromethane (10 ml)
were added triethylamine (139 I, 1.00 mmol) and acetyl chloride (29 1, 0.41
mmol).
After 10 min, the residue was concentrated in vacuo and purified by
preparative HPLC to
provide compound 81 (128 mg, 76%) as a white solid. [M+Hr 480.2, [2M+Nar
981.2,
HPLC purity: 97%.
Example 8b: Preparation of (S)-2-(benzofuran-5-sulfonamido)-6-(N-41,5-
dimethy1-1H-pyrazol-3-yOmethypacetamido)-N,N-diisobutylhexanamide (82)
To a solution of compound 224 (150 mg, 0.34 mmol) in Me0H (4 ml) were added
1,5-dimethylpyrazole-3-carbaldehyde (42 mg, 0.34 mmol), acetic acid (39 p 1 ,
0.68 mmol)
and sodium acetate (56 mg, 0.68 mmol). The mixture was stirred for 30 min at
room
temperature and then treated with sodium borohydride (26 mg, 0.68 mmol). After
1 hr,
saturated aqueous sodium bicarbonate (5 ml) was added to quench the reaction.
The
aqueous phase was extracted with Et0Ac (15 ml) and the organic layer was
washed with
brine (10 ml), dried over anhydrous MgSO4 and concentrated in vacuo. The
residue was
purified by preparative HPLC to provide compound 225 (185 mg, 100%) as a
colorless oil.
[M+Hr 546.3, HPLC purity: 99%.
To a solution of compound 225 (100 mg, 0.18 mmol) in dichloromethane (10 ml)
were added triethylamine (54 1, 0.54 mmol) and acetyl chloride (15 I, 0.22
mmol). After
10 min, the solution was concentrated in vacuo and the residue was purified by
preparative
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
HPLC to provide compound 82 (45 mg, 43%) as a white solid. [M+Hr 588.3, HPLC
purity: 99%.
Example 8c: Preparation of (S)-2-(benzofuran-5-sulfonamido)-6-(N-((1,5-
dimethy1-1H-pyrazol-3-y1)methyl)methylsulfonamido)-N,N-
diisobutylhexanamide (83)
To a solution of compound 225 (30 mg, 0.060 mmol) in dichloromethane (2 ml)
were
added triethylamine (23 IA, 0.16 mmol) and methanesulfonyl chloride (5.04
0.070
mmol). After 10 min, the mixture was concentrated in vacuo and the residue
purified by
preparative TLC to provide compound 83 (24 mg, 70%) as a colorless oil. [M+Hr
624.2,
HPLC purity: 98%.
Example 9: Synthesis of Compounds (84) and (87)
The synthesis of compounds 84 and 87 are outlined in the scheme below. The
individual synthesis of those compounds are described in parts 9a and 9b of
Example 9.
,tOH
BocHNy N-Boc-glycine
1. DIPEA (2 eq), TBTU (1.5 eq)
diisobutylamine (1 eq)
DMF, RT, lh
2. 4 N HCI / dioxane
3. Et3N (2 eq) o
CH2Cl2 ip
cio2s (1.2 eq)
¨N
, NThrN"'KD2mCFO;A(5cecqN),(1 / 1), 80 C
NaH (1.5 eq), 8
-
0- -0
0 0 o _______________________________________________________________ - -
DMF, RT 0
8 o
,N CI
_________________________ 7 (1.2 eq) 0 /
HCI (1.2 eq)
0
0
84
226 87
Example 9a: Preparation of N,N-diisobuty1-2-(N-((1-methyl-M-imidazol-2-
yl)methyl)benzofuran-5-sulfonamido)acetamide (84)
To a solution of N-Boc-glycine (1.0 g, 5.7 mmol) in DMF (10 ml) were added
diisobutylamine (0.10 ml, 11.4 mmol), DIPEA (1.9 ml, 11.4 mmol) and TBTU (2.7
g, 8.5
mmol). The mixture was stirred for 1 hr at room temperature, quenched with
saturated
aqueous sodium bicarbonate (15 ml), and extracted with Et0Ac (20 m1). The
organic
71
CA 02716347 2010-08-23
WO 2009/105774
PCT/US2009/034915
phase was washed with brine (15 ml), dried over anhydrous MgSO4 and
concentrated in
vacuo. The crude material was purified by flash column chromatography (30%
Et0Ac in
hexanes) to provide tert-butyl 2-(diisobutylamino)-2-oxoethylcarbamate (1.6 g,
98%) as a
colorless oil. [M+H] 287.3, HPLC purity: 90%.
To a solution of tert-butyl 2-(diisobutylamino)-2-oxoethylcarbamate (1.6 g,
5.6
mmol) in dichloromethane (15 ml) was added 4N HC1 in dioxane (8 m1). The
mixture was
stirred for 1 hr at room temperature and concentrated in vacuo. To a solution
of the
resulting material in dichloromethane (8 ml) were added triethylamine (1.6 ml,
11.2 mmol)
and benzofuran-5-sulfonyl chloride (1.5 g, 6.7 mmol). After 30 min, water (15
ml) was
added to quench the reaction. The aqueous phase was extracted with
dichloromethane (15
ml) and the organic layer was washed with brine (15 ml), dried over magnesium
sulfate
and concentrated in vacuo. The crude material was purified by flash column
chromatography (40% Et0Ac in hexanes) to provide compound 226 (1.6 g, 78%) as
a
white solid. [M+Hr 367.3, [2M+Nar 755.0, HPLC purity: 99%.
To a solution of compound 226 (89 mg, 0.24 mmol) in DMF (2 ml) were added
sodium hydride (14 mg, 0.36 mmol) and 2-(chloromethyl)-1-methyl-1H-imidazole
HC1 (48
mg, 0.29 mmol). After 1 hr, water (5 ml) was added to quench the reaction. The
aqueous
phase was extracted with Et0Ac (5 ml) and the organic layer was washed with
brine (5
ml), dried over anhydrous MgSO4and concentrated in vacuo. The residue was
purified by
preparative TLC (10% dichloromethane in Me0H) to provide compound 84 (75 mg,
67%)
as a white solid. [M+H] 461.2, HPLC purity: >99%.
Example 9b: Preparation of N,N-diisobuty1-2-(N-(2-(3-methy1-1H-pyrazol-1-
ypethyl)benzofuran-5-sulfonamido)acetamide (87)
To a solution of compound 226 (54 mg, 0.14 mmol) in DMF/acetonitrile (1:1, 4
ml)
were added potassium carbonate (97 mg, 0.70 mmol) and 1-(2-chloroethyl)-3-
methy1-1H-
pyrazole (22 mg, 0.15 mmol) and the resulting mixture stirred at 80 C. After
3 hrs, water
(7 ml) was added to quench the reaction. The aqueous phase was extracted with
Et0Ac (10
ml) and the organic layer was washed with brine (10 ml), dried over anhydrous
MgSO4and
concentrated in vacuo. The crude material was purified by preparative TLC (50%
Et0Ac
in hexanes) to provide compound 87 (35 mg, 53%) as a colorless oil. [M+H]
475.2,
HPLC purity: >99%.
72
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
Example 10: Preparation of (S)-2-(benzofuran-5-sulfonamido)-N,N-diisobuty1-
3-(3-isopropy1-1H-pyrazol-5-yppropanamide (52)
OH SOCl2, Me0H OCH3 1. 4 N HCI / dioxane
HN OCH3
HN HN 0
0 0
0
0 2. TEA (3 eq) 0"0
0 0
0/
41101
227 C102S , 228
N-Boc-L-propargylglycine DCM
0
isobutyl chloride (1.1 eq)
Pd(PPh3)2Cl2 (0.05 eq)
1. LiOH ( 2 eq), THF / water (1 / 1) Cul (0.05 eq), Et3N (3 eq)
HN N toluene, rt HN
2. DIPEA (3 eq) DmF, RT, lh0 0
0' '0
TBTU (1.5 eq), diisobutylamine (1 eq) 0 '0
40 40
0 / 0'
229 230
N/
hydrazine (1 eq),
Me0H
HN
00
o
52
Compound 227 was prepared as described in Organic Letters 2000 Vol 2, No. 24,
3857-3860. To a solution of compound 227 (300 mg, L3 mmol) in dichloromethane
(8 ml)
was added 4N HC1 in dioxane (1 m1). The mixture was stirred for 1 hr at room
temperature and concentrated in vacuo. To a solution of the resulting material
in
dichloromethane (4 ml) were added triethylamine (558 1, 4.0 mmol) and
benzofuran-5-
sulfonyl chloride (429 mg, 1.9 mmol). After 30 min, the mixture was
concentrated in
vacuo. The residue was purified by preparative TLC (50% Et0Ac in hexanes) to
provide
compound 228 (339 mg, 83%) as a colorless oil. [M+111+ 308.0, HPLC purity:
>99%.
To a solution of compound 228 (339 mg, 1.1 mmol) in tetrahydrofuran/water
(1:1,
8 ml) was added lithium hydroxide (53 mg, 2.2 mmol). The mixture was stirred
for 3 hrs at
room temperature, quenched with aqueous 1N HC1 (10 ml) and extracted with
Et0Ac (10
73
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
m1). The organic phase was washed with brine (10 ml), dried over anhydrous
MgSO4 and
concentrated in vacuo. To a solution of the resulting compound in DMF (2 ml)
were added
diisobutylamine (0.20 ml, 1.1 mmol), DIPEA (0.60 ml, 3.3 mmol), and TBTU (620
mg,
1.7 mmol). The mixture was stirred for 1 hr at room temperature, quenched with
saturated
aqueous sodium bicarbonate (10 ml), and extracted with Et0Ac (10 m1). The
organic
phase was washed with brine (10 ml), dried over anhydrous MgSO4 and
concentrated in
vacuo. The crude material was purified by preparative TLC (50% Et0Ac in
hexanes) to
provide compound 229 (102 mg, 23%) as a colorless oil. [M+Hr 405.0, HPLC
purity:
99%.
Compound 52 was prepared using a procedure described in W02005/044817. To a
solution of compound 229 (102 mg, 0.25 mmol), Pd(PPh3)2C12 (9.0 mg, 0.013
mmol) and
CuI (2.5 mg, 0.013 mmol) in triethylamine (104 1 , 0.75 mmol) and toluene (4
ml) was
added isobutyryl chloride (29 1 ,0.28 mmol) at 0 C. The resulting mixture was
stirred at
room temperature overnight and treated with saturated aqueous sodium
bicarbonate (5 m1).
The organic phase was separated, dried over anhydrous MgSO4and concentrated in
vacuo.
The residue was purified by preparative TLC (50% Et0Ac in hexanes) to provide
compound 230 (60 mg, 50%) as a yellowish oil. [M+H] 475.2, [M+Na] 497.2, HPLC
purity: >99%.
To a solution of compound 230 (60 mg, 0.13 mmol) in Me0H (4 ml) was added
hydrazine (5 pl, 0.15 mmol) at 0 C. The resulting mixture was stirred at room
temperature for 30 min and then concentrated in vacuo. The residue was
purified by
preparative HPLC to provide compound 52 (30 mg, 41%) as a brownish oil. [M+Hr
489.2, HPLC purity: >99%.
74
CA 02716347 2010-08-23
WO 2009/105774
PCT/US2009/034915
Example 11: Preparation of (S)-2-(benzofuran-5-sulfonamido)-N,N-diisobuty1-
3-(2-methylthiazol-4-yl)propanamide (62)
0
0
Bn0 1. CH2N HO 2, Me0H 1. A Et0 CI
Br
H)NXrOH ____________________________ H)NXrOCH3
2.10 % Pd/C, H2 ___________ 7
HN
OCH3
0 Et0H 0 0 Et3N, DCM
0 0
2. TMS-diazomethane 0 0o
THF
231 3. 48 % aq HBr 232
N-Boc-L-Asp(Bz0-0H
A
-3y NH2 ) OCH3 1. LiOH in water (6 eq)
THF / Me0H N
rs=-=
HN
Et0H, reflux 2. DIPEA (3 eq) HN
0 0 TBTU (1.5 eq) 0
0 0
diisobutylamine (1 eq)
233 DMF, RT, 1h
234
1. 4 N HCI / dioxane
2. TEA (3 eq) HN
0
0"0
C1028
DCM
0 /
62
To a solution of Boc-L-Asp(Bz1)-OH (5.0 g, 15.5 mmol) in methanol (50 ml) was
added diazomethane (7.8 ml, 15.5 mmol). The mixture was stirred for 1 hr at
room
temperature and concentrated in vacuo. To a solution of the resulting compound
in ethanol
(50 ml) was added 10% palladium on charcoal and the mixture hydrogenated for 3
hrs at
room temperature, filtered through Celite and concentrated in vacuo. The crude
material
was purified by flash column chromatography (30% Et0Ac in hexanes) to provide
compound 231 (2.6 g, 69%) as a white solid. Compound 232 (2.0 g, 65%,
colorless oil)
was prepared as described in Journal of Medicinal Chemistry, 2007, Vol. 50,
No. 8, 1850-
1864.
To a solution of compound 232 (200 mg, 0.62 mmol) in Et0H (4 ml) was added
thioacetamide (40 vtl, 0.68 mmol) and the resulting mixture refluxed at 90 C.
After 16 hrs,
the mixture was concentrated in vacuo. The residue was purified by preparative
TLC (50%
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
Et0Ac in hexanes) to provide compound 233 (100 mg, 53%) as a yellowish oil.
[M+H]
301.0, HPLC purity: 90%.
To a solution of compound 233 (100 mg, 0.33 mmol) in tetrahydrofuran/Me0H
(3:1, 5 ml) was added lithium hydroxide in water (2.5 M, 0.15 ml, 0.36 mmol).
The
mixture was stirred for 3 hrs at room temperature, quenched with aqueous 1N
HC1 (5 ml),
and extracted with Et0Ac (7 m1). The organic phase was washed with brine (5
ml), dried
over anhydrous MgSO4 and concentrated in vacuo. To a solution of the residue
in DMF (2
ml) were added diisobutylamine (57 1, 0.33 mmol), DIPEA (0.17 ml, 0.99 mmol),
and
TBTU (159 mg, 0.49 mmol). The mixture was stirred for 1 hr at room
temperature,
quenched with saturated aqueous sodium bicarbonate (7 ml) and extracted with
Et0Ac (7
m1). The organic phase was washed with brine (10 ml), dried over anhydrous
MgSO4 and
concentrated in vacuo. The crude material was purified by preparative TLC (50%
Et0Ac
in hexanes) to provide compound 234 (83 mg, 64%) as a colorless oil. [M+Hr
398.3,
HPLC purity: 99%.
To a solution of compound 234 (83 mg, 0.21 mmol) in dichloromethane (2 ml) was
added 4N HCI in dioxane (2 m1). The mixture was stirred for 1 hr at room
temperature and
concentrated in vacuo. To a solution of the resulting material in
dichloromethane (4 ml)
were added triethylamine (88 pi, 0.63 mmol) and benzofuran-5-sulfonyl chloride
(68 mg,
0.32 mmol). After 30 min, water (4 ml) was added to quench the reaction. The
aqueous
phase was extracted with dichloromethane (5 ml) and the organic layer was
washed with
brine (4 ml), dried over anhydrous MgSO4 and concentrated in vacuo. The crude
material
was purified by preparative TLC (50% Et0Ac in hexanes) to provide compound 62
(45
mg, 45%) as a white solid. [M+Hr 478.0, [2M+Na] 977.2, HPLC purity: 99%.
76
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
Example 11: Preparation of (S)-2-(benzofuran-5-sulfonamido)-3-(4-((1,3-
dimethy1-1H-pyrazol-5-yl)methoxy)pheny1)-N,N-diisobutylpropanamide (159)
HO00 HO
DIPEA (2 eq)
TBTU (1.5 eq)
1. K2CO3 (5eq) 80 C
+ HN, _________________________ AcCN/DMF = 1/1
OH
HN DMF, RT, 1h HN
0
0 0 0 o CI
I
N-N (1.2 eq)
N-Boc-L-tyrosine 235
Ki
1,1s=N
1.4 N HCI / dioxane
N,
N, HN
HN 0
0
0 0 - 2. TEA (3 eq), DCM 0' '0
0/
C102S 44""
o
236 (1.2 eq)
159
Compound 235 was prepared following the procedure for Scheme 1 except that
instead of Boc-L-3-pyridylalanine N-Boc-L-tyrosine was used as the starting
material. To
a solution of compound 235 (205 mg, 0.52 mmol) in DMF/acetonitrile (1:1, 8 ml)
were
added potassium carbonate (359 mg, 2.6 mmol) and 5-chloromethy1-1,3-
dimethylpyrazole
(90 mg, 0.62 mmol). The mixture was stirred at 80 C. After 3 hrs, water (7
ml) was added
to quench the reaction. The aqueous phase was extracted with Et0Ac (10 ml) and
the
organic layer was washed with brine (10 ml), dried over anhydrous MgSO4 and
then
concentrated in vacuo. The crude material was purified by flash column
chromatography
(50% Et0Ac in hexanes) to provide compound 236 (200 mg, 77%) as a colorless
oil.
[M+H] 501.2, HPLC purity: >99%.
To a solution of compound 236 (200 mg, 0.40 mmol) in dichloromethane (4 ml)
was added 4N HC1 in dioxane (4 m1). The mixture was stirred for 1 hr at room
temperature and concentrated in vacuo. To a solution of the resulting material
in
dichloromethane (4 ml) was added triethylamine (63 I, 0.45 mmol) and
benzofuran-5-
sulfonyl chloride (39 mg, 0.18 mmol). After 30 min, water (5 ml) was added to
quench the
reaction. The aqueous phase was extracted with dichloromethane (5 ml) and the
organic
layer was washed with brine (5 ml), dried over anhydrous MgSO4and then
concentrated in
77
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
vacuo. The crude material was purified by preparative TLC (Et0Ac) to provide
compound
159 (71 mg, 80%) as a white solid. [M+H] 581.3, HPLC purity: >99%.
Example 12: Preparation of (S)-benzofuran-5-ylmethyl 1-(diisobutylamino)-3-
(4-((1,5-dimethy1-1H-pyrazol-3-yl)methoxy)pheny1)-1-oxopropan-2-ylcarbamate
(175)
1. K2003 (5eq)
AcCN/DMF = 1/1 80 C N-N
HOpl
7N-N (1.0 eq)
N,
HN
HN
0 2. 4 N HCI / dioxane 00
0"LO
3. DIPEA (2 eq), CH3CN
0
235
02N
175
? (1.2 eq)
40 204
0
To a solution of compound 235 (197 mg, 0.50 mmol) in DMF/acetonitrile (1:1, 8
ml) were added potassium carbonate (346 mg, 2.50 mmol) and 3-chloromethy1-1,5-
dimethylpyrazole (72 mg, 0.50 mmol). The mixture was stirred at 80 C. After 3
hrs,
10 water (7 ml) was added to quench the reaction. The aqueous phase was
extracted with
Et0Ac (10 ml) and the organic layer was washed with brine (10 ml), dried over
anhydrous
MgS0.4and then concentrated in vacuo. To a solution of the residue in
dichloromethane (4
ml) was added 4N HC1 in dioxane (4 m1). The mixture was stirred for 1 hr at
room
temperature and then concentrated in vacuo. To a solution of the residue in
acetonitrile (4
15 ml) was added DIPEA (49 1.11, 0.28 mmol) and compound 204 (53 mg, 0.17
mmol). After
30 min, water (10 ml) was added to quench the reaction. The aqueous phase was
extracted
with dichloromethane (10 ml) and the organic layer was washed with brine (5
ml), dried
over anhydrous MgSO4 and then concentrated in vacuo. The crude material was
purified
by preparative TLC (10% Me0H in dichloromethane) to provide compound 175 (24
mg,
20 30%) as a colorless oil. [M+H] 575.0, HPLC purity: 98%.
Example 13: Preparation of (S)-2-(benzofuran-5-sulfonamido)-N-(1-(3,3-
dimethyl-N-(pyridin-4-ylmethyl)butanamido)-2-methylpropan-2-y1)-4-
methylpentanamide (28)
78
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
1. DIPEA (3 eq) 1. AcOH (2 eq),
TBTU (1.5 eq) Na0Ac (2 eq),
DMF, RI, 1h
Nr)H2
--
H2NK'''OH N (1 eq)
(1 eq) 2. NaBH4 (2 eq)
F-11\71))r Me0H
0
0 0
0 0 2. Dess-Martin (2 eq) 0 0 3. Et3N
(3eq) 0 0
DCM, RT tert-butylacetyl
chloride (1.5 eq)
N-Boc-L-leucine 237 238
1.4 N HCI in dioxane, DCM
HNNN
2. TEA (3 eq)
0"0n
oz
.02s
DCM
0
28
To a solution of Boc-L-leucine (1.0 g, 4.0 mmol) in DMF (4 ml) were added 2-
amino-2-methyl-1-propanol (382 tl, 4.0 mmol), DIPEA (2.1 ml, 12.0 mmol) and
TBTU
5 (1.9 g, 6.0 mmol). T he mixture was stirred for 1 hr at room temperature,
quenched with
saturated aqueous sodium bicarbonate (15 ml), and extracted with Et0Ac (20
m1). The
organic phase was washed with brine (15 ml), dried over anhydrous MgSO4and
concentrated in vacuo. To a solution of the residue in dichloromethane (12 ml)
was added
Dess-Martin periodinane (3.3 g, 8.0 mmol). The mixture was stirred for 2 hrs
at room
10 temperature. The mixture was concentrated in vacuo. The residue was
purified by flash
column chromatography (50% Et0Ac in hexanes) to provide compound 237 (620 mg,
53%) as a white solid. [M+H] 301.2, HPLC purity: 98%.
To a solution of compound 237 (123 mg, 0.41 mmol) in methanol (3 ml) were
added 4-(aminomethyl)pyridine (41 p1, 0.41 mmol), acetic acid (24 ul , 0.41
mmol) and
15 sodium acetate (34 mg, 0.41 mmol). The mixture was stirred for 30 min at
room
temperature and then treated with sodium borohydride (31 mg, 0.82 mmol). After
1 hr,
saturated aqueous sodium bicarbonate (5 ml) was added to quench the reaction.
The
aqueous phase was extracted with Et0Ac (8 ml) and the organic layer was washed
with
brine (5 ml), dried over anhydrous MgSO4 and concentrated in vacuo. To a
solution of the
20 resulting material in dichloromethane (2 ml) were added triethylamine
(71 p1, 0.51 mmol)
and tert-butylacetyl chloride (36 ul, 0.26 mmol). The mixture was stirred for
1 hr at room
temperature and concentrated in vacuo. The residue was purified by flash
column
79
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
chromatography (50% Et0Ac in hexanes) to provide compound 238 (49 mg, 59%) as
a
white solid. [M+Hr 491.2, [M+Nar 513.3, HPLC purity: 98%.
To a solution of compound 238 (49 mg, 0.10 mmol) in dichloromethane (2 ml) was
added 4N HC1 in dioxane (2 m1). The mixture was stirred for 1 hr at room
temperature and
then concentrated in vacuo. To a solution of the resulting material in
dichloromethane (4
ml) were added triethylamine (42 111, 0.32 mmol) and benzofuran-5-sulfonyl
chloride (32
mg, 0.15 mmol). After 30 min, water (4 ml) was added to quench the reaction.
The
aqueous phase was extracted with dichloromethane (5 ml) and the organic layer
was
washed with brine (4 ml), dried over anhydrous MgSO4 and concentrated in
vacuo. The
crude material was purified by preparative TLC (50% Et0Ac in hexanes) to
provide
compound 28 (31 mg, 53%) as a white solid. [M+Hr 571.2, [M+Nar 593.3, HPLC
purity: 98%
Example 14: Synthesis of Compounds (6) and (7)
The synthesis of compounds 6 and 7 are outlined in the scheme below. The
individual synthesis of those compounds are described in parts 14a, and 14b of
Example
14.
HN 239
101 s,
OH
HN 0 HN
0
0 0 DIPEA (3 eq) 0 el
TBTU (1.5 eq) 0
DMF, RT, 1h
N-Boc-L-Phe-OH 6 0
1. 4 N HCI in dioxane, DCM HN
r(LC' 40
2. DIPEA (3 eq)
TBTU (1.5 eq) HN O
y
DMF, RT, lh .0 0
Boc-L-3-(3-pyridyl)alanine (1 eq)
7
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
Example 14a: Preparation of (S)-tert-butyl 1-((benzofuran-5-ylmethyl)((2-
methylthiazol-4-yl)methyl)amino)-1-oxo-3-phenylpropan-2-ylcarbamate (6)
To a solution of benzofuran-5-yl-methylamine (65 mg, 0.44 mmol) in Me0H (4
ml) were added 2-methyl-1,3-thiazole-4-carbaldehyde (56 mg, 0.44 mmol), acetic
acid (25
it1, 0.44 mmol) and sodium acetate (36 mg, 0.44 mmol). The mixture was stirred
for 30
min at room temperature and treated with sodium borohydride (33 mg, 0.88
mmol). After
1 hr, aqueous sodium bicarbonate (5 ml) was added to quench the reaction. The
aqueous
phase was extracted with Et0Ac (7 ml) and the organic layer was washed with
brine (5
ml), dried over anhydrous MgSO4 and concentrated in vacuo. The crude material
was
purified by preparative TLC (10% Me0H in dichloromethane) to provide compound
239
(77mg, 68%) as a white solid. [M+H] 259.0, HPLC purity: >99%.
To a solution of Boc-L-Phe-OH (41 mg, 0.15 mmol) in DMF (1 ml) were added
compound 239 (40 mg, 0.15 mmol), DIPEA (79 tl, 0.45 mmol), and TBTU (86 mg,
0.22
mmol). The mixture was stirred for 1 hr at room temperature, quenched with
saturated
aqueous sodium bicarbonate (7 ml), and extracted with Et0Ac (4 m1). The
organic phase
was washed with brine (7 ml), dried over anhydrous MgSO4and concentrated in
vacuo.
The crude material was purified by preparative TLC (30% Et0Ac in hexanes) to
provide
compound 6 (53 mg, 67%) as a white solid. [M+H] 506.0, [M+Na] 528.0, HPLC
purity: >99%.
Example 14b: Preparation of tert-butyl (S)-14(S)-1-((benzofuran-5-
ylmethy1)((2-methylthiazol-4-Amethyl)amino)-1-oxo-3-phenylpropan-2-
ylamino)-1-oxo-3-(pyridin-3-yppropan-2-ylearbamate (7)
To a solution of compound 6 (30 mg, 0.06 mmol) in dichloromethane (2 ml) was
added 4N HC1 in dioxane (2 m1). The mixture was stirred for 1 hr at room
temperature and
then concentrated in vacuo. To a solution of residue in DMF (2 ml) were added
N-Boc-L-
3-(3-pyridyl)alanine (16 mg, 0.06 mmol), DIPEA (31 [tl, 0.18 mmol), and TBTU
(34 mg,
0.090 mmol). The mixture was stirred for 1 hr at room temperature, quenched
with
saturated aqueous sodium bicarbonate (7 ml) and extracted with Et0Ac (7 m1).
The
organic phase was washed with brine (10 ml), dried over anhydrous MgSatand
concentrated in vacuo. The residue was purified by preparative TLC (Et0Ac) to
provide
compound 7 (22 mg, 56%) as a white solid. [M+H] 654.3, HPLC purity: 99%.
81
CA 02716347 2010-08-23
WO 2009/105774 PCT/US2009/034915
Example 15: A General procedure
Compounds of formula (I) bearing benzofuranyl groups at the alpha carbon may
generally be prepared by the following procedure from benzofurylalanine, as
follows.
D-Benzofurylalanine.HC1 is dissolved in water and reacted with (Boc)20 and 2
eq.
1N NaOH. After the completion of the reaction, solvent is removed in vacuo and
the crude
product purified to furnish the Bac derivative. This compound is reacted with
a primary or
a secondary amine (1 eq), TBTU (1.5 eq) and Et3N (3 eq) in anhydrous DMF.
After the
completion of the reaction DMF is removed in vacuo and the crude material is
purified to
furnish the amide. The amide is reacted with 20% TFA/CH2C12 at room
temperature. After
the completion of the reaction, solvent is removed in vacuo and the residue is
reacted with
a carbonyl or sulfonyl chloride (1 eq), Et3N (3 eq), and DMAP in CH2Cl2. After
completion of the reaction solvent is removed and the crude product purified
to furnish the
target compound(s).
The preparation of D-benzofurylalanine for use in this general procedure may
be
conducted as described in the following example.
Example 16: Synthesis of D-benzofuryl alanine
OFIC
NaBH4
0. HO SOCI a
2 CI al \
Wo Me0H, RT 0 CH2C12, RT 0
H2N,ThrOH
0
A solution of 5-benzofurancarboxaldehyde (10 g, 68 mmol) in Me0H (40 mL) was
cooled in an ice bath. NaBH4 (3.84 g, 102 mmol) was added over a period of 2
hr and
stirring continued for 20 min. Saturated NH4C1 was added. The mixture was
suspended in
ethyl acetate (100 mL) and the solid was filtered off. The solution was
concentrated,
partitioned between ethyl acetate and brine, dried over anhydrous Na2SO4,
concentrated
and dried under high vacuum to furnish benzofuran-5-ylmethanol (10 g, 100%) as
a solid,
which was taken up in CH2C12 (60 mL) to which SOC12 (5.9 mL, 81 mmol) was
added at
room temperature. The reaction mixture was stirred for 3 hr. The reaction
mixture was
diluted with CH2C12, washed with a saturated solution of NaHCO3, then brine,
dried over
anhydrous Na2SO4, and concentrated in vacua to furnish 5-
chloromethylbenzofuran (10 g,
90%) as an oil. This material was used without further purification to
synthesize D-
benzofurylalanine according to C. Behrens, Tetrahedron 56 (2000), 9443-9449.
82
CA 02716347 2010-08-23
WO 2009/105774
PCT/US2009/034915
Example 17: Synthesis of Compounds (161) and (164)
The synthesis of compounds 161 and 162 are outlined in the scheme below. The
individual synthesis of those compounds are described in parts 17a and 17b of
Example 17.
0
0
o
IF iir -rsie (¨
Boc,20, NaOH 1) TFA/CH2C12
2) Et3NDMAP, D N
\
- HN N
TBTU, Et3N, DMF HteyN y" , I-12a2
HCI H20, RT 0 µ---S SO2CI
0 0 0 0
0
+192
161 0 164
Example 17a: Preparation of (R)-tert-butyl 3-(benzofuran-5-y1)-1-(isobutyl((2-
methylthiazol-4-yl)methypamino)-1-oxopropan-2-ylcarbamate
To a solution of D-benzofurylalanine.HC1 (3.00 g, 12.4 mmol) in water (150 mL)
was added 1N NaOH (25 mL) followed by di-tert-butyl dicarbonate (3.00 g, 13.7
mmol)
and the mixture was stirred at RT for 20 hr. The pH was adjusted to 3 by the
addition of 2
N HC1 and the mixture then extracted with ethyl acetate. The combined organic
layers
were washed with brine, dried over anhydrous Na2SO4 and the solvent evaporated
in
vacuo. The crude material was purified by flash column chromatography using
10%
Me0H in CH2C12 to furnish 2.2 g (58%) of compound 192 [M-111- 304.0, [M+H]-
Boc
206Ø
A solution of compound 192 (40 mg, 0.13 mmol), TBTU (63 mg, 195 mmol) and
Et3N in DMF (2 mL) was stirred at RT for 20 min and then added to a solution
of 2-
methyl-N-((2-methylthiazol-4-yl)methyl)methan-1-amine (24 mg, 0.13 mmol) in
DMF (2
mL) and the resulting mixture stirred at RT for 3 hr. The DMF was removed in
vacuo and
the crude material was purified by Prep TLC using 4% Me0H in CH2C12 to furnish
45 mg
(74%) of compound 161 as a white solid [M+Hr 472.0, HPLC purity 95%.
Example 17b: Preparation of (R)-2-(benzofuran-5-sulfonamido)-3-
(benzofuran-5-y1)-N-isobutyl-N-((2-methylthiazol-4-yl)methyl)propanamide
164
Compound 161 (30 mg, 0.064 mmol) was stirred with 20% TFA/CH2C12 (5 mL) at
RT for 20 min and then concentrated in vacuo to furnish the amine TFA salt. 10
mg (0.021
mmol) of this compound, Et3N (9.0 L, 0.063 mmol) and DMAP (1 mg, 0.008 mmol)
in
CH2C12 (1 mL) were added to a cold (ice bath) solution of 5-
benzofuransulfonylchloride
(5.4 mg, 0.025 mmol) in CH2C12 (1 mL). The reaction mixture was warmed to RT
and
stirred for 20 min. It was then concentrated in vacuo and the residue purified
by Prep TLC
83
CA 02716347 2015-08-18
using 4% Me0H in CH2C12 to furnish 9.0 mg (78%) compound 164 as a white solid
[M+Hr 552.0, HPLC purity 95%.
The scope of the claims should not be limited by the preferred embodiments and
examples, but should be given the broadest interpretation consistent with the
description
as a whole.
84
